








Functional characterization of B- and T 
lymphocytes after aCD20 treatment in two 











In partial fulfillment of the requirements for the degree 




in the Molecular Medicine Study Program 






















MEMBERS OF THE THESIS COMMITTEE:  
 
 
First member of the thesis committee and supervision: 
Prof. Dr. Marin S. Weber  
Department of Neuropathology  
University Medical Center, Georg-August-University Göttingen  
 
Second member of the thesis committee  
Prof. Dr. Jürgen Wienands  
Department of Cellular and Molecular Immunology 
University Medical Center, Georg-August-University Göttingen  
 
Third member of the thesis committee  
Prof. Dr. Dieter Kube  
Department of Hematology and Oncology  















Here I declare that my doctoral thesis entitled “Functional characterization of B- and T 
lymphocytes after aCD20 treatment in two different EAE models” has been written 

























In Erinnerung an  





List of Publications 
 
Original acticles 
Kinzel, S., Lehmann-Horn, K., Torke, S., Häusler, D., Winkler, A., Stadelmann, C., Payne, N., 
Feldmann, L., Saiz, A., Reindl, M., et al. (2016). Myelin-reactive antibodies initiate T cell-
mediated CNS autoimmune disease by opsonization of endogenous antigen. Acta Neuropathol. 
(Berl.) 132, 43–58 
Lehmann-Horn K., Kinzel S., Feldmann L., Radelfahr F., Hemmer B., Traffehn S., Bernard CC., 
Stadelmann C., Brück W., Weber MS. (2014). Intrathecal anti-CD20 efficiently depletes 
meningeal B cells in CNS autoimmunity. AnnClin Tranl Neurol. 1(7) 490-96 
Winterberg T, Vieten G, Feldmann L, Yu Y, Hansen G, Hennig C, Ure BM, Kuebler JF.(2014). 
Neonatal murine macrophages show enhanced chemotactic capacity upon toll-like receptor 
stimulation. Pediatr Surg Int. 2014 Feb;30(2):159-64.  
 
Abstracts 
Feldmann L., Zamvil S., Brück W., Weber MS. 
Enrichment of B cells with pro-inflammatory properties following anti-CD20 mediated B cell 
depletion in an EAE model actively involving B cells 
13th Congress of the International Society of Neuroimmunology, September 26th-29th 2016, 
Jerusalem, Israel, Poster session 
Feldmann L., Zamvil S., Brück W., Weber MS. 
Enrichment of B cells with pro-inflammatory properties following anti-CD20 mediated B cell 
depletion in an EAE model actively involving B cells  
12th European Committee for Treatment and Research In Multiple Sclerosis, October 7th-10th 
2015, Barcelona, Spain, Poster session 
 
Feldmann L., Weber MS.  
Following anti-CD20 treatment, compartment-specific repletion with immune-competent B 
cells depends on activation of reappearing B cells  
13th Congress of the International Society of Neuroimmunology, September 26th-29th 2014, 





Table of contents 
1. Introduction ......................................................................................................................................... 1 
1.1.Multiple sclerosis ........................................................................................................................... 1 
1.1.2. History and Epidemiology...................................................................................................... 1 
1.1.3. Clinical course ........................................................................................................................ 1 
1.1.4. Pathogenesis of MS ............................................................................................................... 3 
1.1.5. Histopathology of MS ............................................................................................................ 5 
1.1.6. Current MS therapies ............................................................................................................ 6 
1.1.7. B cell depleting therapy ......................................................................................................... 7 
1.2. Experimental autoimmune disease (EAE) .................................................................................. 10 
1.2.1. Pathogenesis of EAE ............................................................................................................ 10 
1.2.2. B cell function EAE ............................................................................................................... 11 
2. Material and Methods ....................................................................................................................... 14 
2.1. Material ...................................................................................................................................... 14 
2.1.1 Reagents ............................................................................................................................... 14 
2.1.2. Solution ................................................................................................................................ 16 
2.1.3. Protein enzymes and inhibitors ........................................................................................... 18 
2.1.4. Monoclonal antibodies for flowcytometry.......................................................................... 18 
2.1.5. Monoclonal antibodies for antigen independent activation in vitro .................................. 19 
2.1.6. Primary antibodies for immunohistochemical staining ...................................................... 19 
2.1.7. Secodary antibodies for immunohistochemical staining .................................................... 20 
2.1.8. Applied Kits .......................................................................................................................... 20 
2.1.9. Primers ................................................................................................................................ 20 
2.1.10. Consumables ..................................................................................................................... 20 
2.1.11. Technical devices ............................................................................................................... 21 
2.1.12. Software ............................................................................................................................ 22 
2.1.13. Mice ....................................................................................................................................... 23 
2.2. Methods ..................................................................................................................................... 23 
2.2.1. Genotyping of genetically modified mice of 2D2 ................................................................ 23 
2.2.2. B cell depletion by aCD20 treatment .................................................................................. 24 
2.2.3. Experimental autoimmune encephalomyelitis ................................................................... 24 
2.2.4. Clinical EAE score ................................................................................................................. 24 
2.2.5. Preparation of a single cell suspension for characterization of remaining and reappearing 
B- and T cells .................................................................................................................................. 24 
2.2.6. Characterization of B cells and T cells after aCD20 treatment ............................................ 26 




2.2.8. In vivo proliferation experiments ........................................................................................ 28 
2.2.9. ELISA .................................................................................................................................... 28 
2.2.10. Histology ............................................................................................................................ 29 
2.2.11. Statistical analysis and data analyzation ........................................................................... 30 
3. Results ............................................................................................................................................... 31 
3.1. Analysing depletion and repletion of B cells after aCD20 treatment ........................................ 31 
3.1.1. Characterization of remaining B cells after aCD20 treatment ............................................ 31 
3.1.2. B cell repletion in naïve mice .............................................................................................. 34 
3.1.3. B cell repletion in the EAE models ....................................................................................... 36 
3.1.4. Clinical score after aCD20 treatment in the EAE model ...................................................... 38 
3.1.5. Characterization of reappearing B cells in EAE ....................................................................... 40 
3.1.5.1. Phenotyping of reappearing B cells in EAE ....................................................................... 40 
3.1.5.2. Cytokine release after LPS or CpG stimulation ................................................................. 43 
3.1.5.3 Higher rMOG binding ability of reappearing B cells in rMOG EAE .................................... 44 
3.1.6. Functional characterization of reappearing B cells in two EAE models .................................. 46 
3.1.6.1. Superior antigen presenting function of reappearing B cells in rMOG EAE ..................... 46 
3.1.6.2. Cytokine release during antigen presentation ................................................................. 48 
3.1.7. In vivo proliferation of B cells after aCD20 treatment ............................................................ 51 
3.1.7.1 Increased in vivo proliferation after aCD20 depletion in the EAE model ......................... 51 
3.1.7.2. In vivo proliferation of B and T cells 8 weeks after aCD20 Ab treatment ........................ 53 
3.2. Direct and indirect effects on T cells after aCD20 treatment .................................................... 55 
3.2.1. Dynamics of the T cell population during B cell repletion .................................................. 55 
3.2.2. Characterization of the T cell population after aCD20 treatment ...................................... 57 
3.2.3. CD20+ T cell repletion ......................................................................................................... 60 
3.2.4. CD20+ T cell repletion in EAE .............................................................................................. 62 
3.2.5. Direct stimulation of T cells of naïve mice after aCD20 treatment ex vivo ......................... 63 
3.2.6. Direct ex vivo stimulation of T cells in EAE after aCD20 treatment .................................... 66 
3.3. CNS infiltration of B cells, T cells and myeloid cells in the dynamics of B cell repletion in EAE . 68 
4. Discussion .......................................................................................................................................... 71 
4.1. Enrichment of CD27+ activated B cells after aCD20 treatment ................................................. 71 
4.2. Reappearance of activated B cells causes clinical worsening of rMOG EAE and a different 
distribution of reappearing B cells during repletion in the immune relevant compartments .......... 73 
4.3. Reappearing B cells show a more activated phenotype in B cell-mediated EAE ....................... 74 
4.4. Dynamic of T cells during B cell depletion and repletion after aCD20 treatment ..................... 79 
4.5. Direct stimulation of T cells after aCD20 treatment ex vivo ...................................................... 80 












Ein großer Dank geht an Prof. Dr. Martin S. Weber, dem ich auch dafür danke dass er mich mit 
diesem Projekt betraut hat. Die Arbeit mit dir hat mich sowohl in professioneller als auch in 
persönlicher Hinsicht sehr vorangebracht. Ich hatte eine sehr schöne Zeit in deiner 
Arbeitsgruppe.  
 
Ich bedanke mich sehr bei Prof. Dr. Wolfgang Brück für die Gelegenheit meine Doktorarbeit in 
dem Institut für Neuropathologie anzufertigen  
 
Des Weiteren bedanke ich mich auch bei Prof. Dr. Jürgen Wienands und Prof. Dr. Dieter Kube 
für Ihr Interesse und kritischen Anmerkungen während der Thesis committee Treffen.  
 
Ich bedanke mich auch sehr bei Cynthia und Heidi für ihre Hilfe sowie den Mitarbeitern des 
Promotionsprogrammes Molekulare Medizin, vor allem Dr. Erik Meskauskas.  
 
Ein riesiger Dank geht an Caroline Jaß, Jan Einar Albin, Julian Koch, Mareike Gloth und Katja 
Grondey, ohne deren großartige Unterstützung und übermäßiges Engagement einige 
Experimente nicht durchführbar gewesen wären. Zudem danke ich euch für viele lustige 
Stunden im Labor die mir den Alltag versüßt haben. 
Ein großer Dank geht an Darius dafür dass du mir mit deinem professionellen Rat immer 
geholfen hast.  
Ich bedanke mich sehr bei meinen Kolleginnen Lena und Anne die von Anfang an dafür sorgten, 
dass ich mich herzlich aufgenommen gefühlt habe und mir mit ihrer professionellen Meinung 
zur Seite standen. 
 
Außerdem möchte ich mich wirklich sehr bei Sarah, Basti und Kim bedanken. Ihr seid in den 
letzten Jahren viel mehr als nur Kollegen für mich geworden! 
Kim, nicht nur das du immer ein offenes Ohr und gute Ratschläge als Freundin für mich hattest 
sondern du bist sogar Teil meiner Familie geworden! Vielen Dank für deine Unterstüzung in allen 
Lebenslagen! 
Basti, ich bedanke mich für sehr viele lustige Stunden im Büro! Du hast den Alltag sehr viel 
erträglicher gemacht und standest mit Rat und Tat immer zur Seite!  
Sarah, meine Nummer 1! Du bist in den letzten Jahren einer der wichtigsten Personen geworden 
und warst immer für mich da und hast mich privat als auch professionell immer unterstützt ohne 
Wenn und Aber! Ich danke dir dafür aus ganzen Herzen! 
 
Ich bedanke mich bei meinen Freunden Helene und Maleen. Ihr wart immer für mich da sowohl 
mit aufbauenden Worten als auch guten Ratschlägen! 
Ein sehr großer Dank geht an Matzie! Seit 10 Jahren bist du immer an meiner Seite und gibst mir 
Halt! 
 
Ein großer Dank geht an meine Familie. 
Ich danke meinen verstorbenen Eltern, Uwe, Marvin, David und Jenny für eure Unterstützung 
ohne euch wäre das nicht möglich gewesen. 






Multiple sclerosis (MS) is one of the most common causes of persisting disability in young adults. 
Its clinical course can be heterogeneous with a varying extent of inflammatory central nervous 
system (CNS) lesions, demyelination and axonal loss accumulating over time. Earlier concepts 
assumed that MS is primarily a T cell driven disease. Current evidence suggests that B cells may 
play an equally important role in MS pathogenesis. This notion was boosted by the extensive 
and rapid benefit of B cell depletion via anti-CD20 antibodies in recent clinical trials in patients 
with relapsing, remitting MS. Notwithstanding these results, it is currently not clear whether 
patients with MS and related disorders need to be permanently depleted of B cells to maintain 
clinical stabilisation. As the related mechanistic question, it is thus far unknown when B cells 
reappear in compartments other than the blood and in particular, in what functional status B 
cells return upon cessation of anti-CD20 treatment. To address these questions, we utilized two 
murine MS models of experimental autoimmune encephalomyelitis (EAE), one in which B cells 
remain naïve, and one on which B cells get actively involved in a pathogenic manner. Using these 
opposing models, we monitored reappearance of B cells as well as their functional phenotype 
in bone marrow, spleen, lymph node, blood as well as the CNS. First, and independent of the 
model used, we observed that B cells reappeared in bone marrow and spleen substantially prior 
to the blood, which indicates that monitoring B cells in the blood of patients may not be a 
suitable strategy to assess B cell reappearance. Second, we observed that despite extensive anti-
CD20 treatment, a population of CD20+ B cells remained un-depletable in the spleen of mice 
with EAE. These B cells were found to be differentiated and antigen-experienced germinal center 
B cells, while naïve B cells were rarely detected. Of note, this finding was pronounced in the EAE 
model in which B cells are activated.  Upon recovery from anti-CD20 treatment, this population 
strongly expanded in vivo in parallel to de novo generation of naïve B cells in the bone marrow. 
I consequence, we observed that upon return of B cells, mice which had received the B cell-
involving EAE induction regimen contained a higher ratio of antigen-activated / naïve B cells 
when compared to the EAE model in which B cells remain naïve. Functionally, this translated 
into an enhanced antigen-presenting function of reappearing B cells in the B cell-EAE model. 
These findings indicate that in a B cell activating milieu, remaining antigen-experienced B cells 
can expand in secondary organs after anti-CD20 treatment, which may result in a relative shift 
towards pro-inflammatory B cell function when compared to the status of B cells prior to 
depletion.  
Recent findings suggest that besides B cells, a small population of differentiated human T cells 
express CD20. To date it is not clear whether these T cells play a pathogenic role in MS. Following 
this observation mechanistically, we could detect that mice with EAE indeed contain a 
population of CD20+ T cells, which is rapidly depleted upon anti-CD20 treatment. Paralleling the 
compartment-specific repletion of B cells, CD20+ T cells sequentially reoccurred in spleen, lymph 
nodes and blood after anti CD20 treatment. Further studies aim to dissect to what extent 
depletion of these T cells may possibly contribute to the clinical benefit of anti-CD20 treatment 
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Multiple sclerosis (MS) is one of the most common inflammatory diseases of the central nervous 
system (CNS) in young adults in the western world, affecting about 2.5 million patients1. MS is 
characterized by inflammation of the CNS, demyelination and axonal loss resulting in 
neurodegeneration. MS is a heterogeneous disease and its trigger is still unknown. The extent 
of heterogeneity became clear by characterizing neuro myelitis optica (NMO) as a sub type of 
MS for years, which is now known to be triggered by aquaporin-4 antibodies. 
1.1.2. History and Epidemiology 
MS was first described by Robert Carswell in 1838. A more detailed description of MS was 
published by Jean Cruveillier in his manuscript “Anatomie pathologique du corps human” (1829-
1842)2. However, the first correlation between the clinical symptoms and pathological features, 
such as inflammation, demyelination and axonal loss was made by Jean Martin Charcot in 18683. 
The risk to develop MS increases with the distance to the equator. Areas with an elevated 
prevalence of MS are Europe, Russia, Israel, Northern US, Canada and New Zealand4. The 
prevalence of MS in Germany is around 127 out of 100000 citizen5. The average age at disease 
onset is 29 years and females are affected twice as often as males6. 
Until today, the exact cause of MS is unknown but many risk factors were described. There is 
evidence for environmental, genetic, hormonal and/or infectious factors which are linked with 
MS. A genetic factor of MS is the HLAII gene which is known to be associated with the risk to 
develop MS since the 1970s7. Investigating environmental factors, low vitamin D levels were 
identified as a possible risk factor for MS, while higher serum levels of vitamin D seem to reduce 
the relapse rate8–11. Additionally, the infection with Epstein-Barr virus (EBV) is controversially 
discussed as a risk factor but due to a low number of uninfected patients, it is challenging to 
investigate12. Furthermore, smoking is known to elevate the risk to develop MS and to fasten 
the transition from relapsing remitting MS to secondary progressive MS13–15. 
1.1.3. Clinical course  
MS is a heterogeneous disease. For a better communication and to avoid ambiguities, the MS 
society advisory committee distinguished four different subtypes of clinical courses in 1996 and 
revised these in 201416,17. The classical four subtypes are described as followed: 
The relapsing remitting (RRMS) form is the most common disease course, affecting around 85% 
of all patients at the onset of disease. It is defined by clinical relapses from which patients can 
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fully or partially recover (remission) (figure 1)16. A relapse is defined as an episode of 
neurological symptoms typical for an inflammatory demyelinating event in the CNS that lasts for 
at least 24 hours in the absence of fever or infection. 
Most of the patients with RRMS transit over time into secondary progressive MS (SPMS) which 
is characterized by continuous worsening of disease and relapses with minor recovery phases 18. 
A further type of MS is the primary progressive MS (PPMS) which is characterized by continuous 
progression of the disease from the onset without any phases of recovery. Only about 10% of 
MS patients are affected by this subtype19. The last type of MS is the primary relapsing MS 
(PRMS). It is the rarest type of MS and is defined by progression from disease onset combined 
with relapses which are followed by incomplete recovery. 
The revised classification is focused on RR disease or progressive disease. The precursor state of 
RRMS is the clinically isolated syndrome (CIS). CIS shows inflammatory demyelination that can 
develop to MS, but has not yet fulfilled the criteria of dissemination. In case CIS additionally 
shows activation, which is determined by clinical relapses and/or MRI activity, it can progress to 
RRMS whether such activity fulfils the criteria of dissemination. 
Progression of disease is characterized by clinical evaluation with continuous disease 
progression. Whether multiple assessments are not possible, activity and progression are 
“indeterminate”. If PPMS patients show further activity but no progression, they are described 
as PPMS-without progression. SPMS patients that show progression but no activity or show 
neither progression nor activity are defined as stable17. 
 
Figure 1: Classical MS subtypes 
A) relapsing remitting MS B) secondary progressive MS C) primary progressive MS D) 
progressive remitting MS (modified from Lublin et al., 199616, and adapted from Häusler20) 
  
  1. Introduction 
3 
 
1.1.4. Pathogenesis of MS 
The exact factors which trigger MS are still unknown. Researchers try to investigate the disease 
using different animal models. Many of the mechanisms of MS are investigated in the 
inflammatory animal model experimental autoimmune encephalomyelitis (EAE). Reviewing 
experimental data of EAE, we have to keep in mind the differences between EAE and MS as well 
as the complexity of MS. 
Findings in EAE model show that immune cells infiltrate in the CNS and cause a pro-inflammatory 
immune response21. T cells are reported to be the first activated cells which infiltrate the CNS. 
These autoimmune T cells release pro-inflammatory cytokines such as tumor necrosis factor-α 
(TNF-α) and interferon β (IFNβ)22. This pro-inflammatory milieu leads to an activation of 
endothelial cells of the blood brain barrier (BBB) which lead to upregulation of cell adhesion 
molecules (CAM)23. This upregulation of CAM attracts more immune cells of the periphery such 
as monocytes, B and T cells, plasma cells and dendritic cells (DC) which invade into the CNS. This 
invasion of immune cells causes inflammation which interferes with the astroglial and 
oligodendroglial homeostasis. Autoimmune antibodies, released by infiltrating plasma cells, 
might lead to the damage of glial cells and the myelin sheath21. Further axonal damage and injury 
of the myelin sheath can be caused by release of reactive oxygen of microglia and 
macrophages24. 
The initiation of the disease by T cells, however, is just one of the hypothesized mechanisms but 
there is evidence that different T cell subtypes influence the pathogenesis of MS. It is known 
that pro-inflammatory T helper 1 (Th1) and T helper 17 (Th17) cells can induce EAE by adoptive 
transfer of these cells. Th17 are able to release IL-17A, IL-17F, IL-21, IL-9, IL-22 and TNF-α and 
can be found in lesions of MS patients25,26. In contrast, T helper 2 (Th2) cells show an anti-
inflammatory function by released anti-inflammatory cytokines such as IL-4 and IL-13, for 
example after being activated by type II monocytes27. 
Regulatory T cells also appear to be implicit in the pathogenesis of MS. The suppressive function 
of regulatory T cells is profoundly compromised in MS patients, which possibly might contribute 
to the pathogenic activation of Th1 and Th17 cells 28,29. 
 
1.1.4.1. Role of B cells in MS 
For decades, MS was thought to be a mainly T cell driven disease. Therefore B cells were believed 
to play only a secondary role by releasing autoimmune antibodies. However, more recent 
studies suggest an important function of B cells in MS. The success of B cell depleting therapies 
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in patients with RRMS particularly brought B cells into the focus of MS research for their possible 
importance in MS pathogenesis. 
The earliest indication that B cells contribute to MS pathology dates back to the detection of 
intrathecal IgGs with moving boundary electrophoresis by Elvin Kabat in 194230. These 
oligoclonal bands (OBCs) in the cerebrospinal fluid (CSF), caused by expansion of B cells and 
plasma cells, can be detected in more than 95% of MS patients31. 
Furthermore, accumulations of B cells were found in the meninges of patients with SPMS. They 
are located in follicular like structures together with follicular dendritic cells and T cells32,33. 
However, the strongest evidence for the role of B cell in the pathogenesis of MS is the rapid 
clinical benefit of B cell depletion by aCD20 antibodies as shown in 2008 by Hauser et al.34. After 
aCD20 Ab treatment, a relative reduction in gadolinium-enhancing lesions by 91 % could be 
observed in patients with RRMS. Accordingly, the number of new lesions was reduced in this 
study34. 
A closer look at the mechanism of aCD20 depletion reveals that the release of autoimmune 
antibodies is not altered substantially because CD20 is not expressed on plasma cells which 
produce and release autoimmune antibodies35,36. 
The fact that plasma cells are not affected by aCD20 therapy suggest an additional B cell function 
that influences the pathogenesis of MS. One important function of B cells is their ability to 
present antigens to T cells which influence the pathogenesis of MS. For antigen presentation 
and subsequent T cell priming, major histocompatibility complex II and the costimulatory 
molecules of CD80, CD86 and CD40 are necessary. In MS patients, these co-stimulatory 
molecules are known to be upregulated37. Furthermore, the cytokine profile of MS patients is 
dysregulated. Barr et al.38 show that B cells release more pro-inflammatory IL-6 and tumour 
necrosis factor alpha3736. These cytokines are reported to induce pathogenic Th1 and Th17 cell 
differentiation which can cause demyelination and axonal loss39. After B cell depleting therapies, 
the levels of pro-inflammatory cytokines in patients are decreased40. 
This shows that B cells might play a role in the pathogenesis of MS. But current studies report 
the presence of CD20+ T cell population which depletable by aCD20 treatment41. Holley et al.42 
show the presence of these CD20+ T cells in the brain as well as in the blood of RRMS patients. 
The influence and depletability of this CD20+ T cells might also explain the benefit of aCD20 
depleting therapy or a combination of B cell and CD20+ T cell depletion causes successful 
treatment. However, the extract mechanism of aCD20 treatment is still not fully understood 
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1.1.5. Histopathology of MS 
The pathology of MS is characterized by typical multifocal lesions in the CNS. Typical hallmarks 
are infiltration of immune cells, white matter demyelination, reactive gliosis and relative axonal 
preservation. Traditionally, MS lesions are classified according to their density and location. 
Active lesions are characterized by pronounced macrophages infiltration whereas chronic active 
lesions show a hypocellular centre and an inflammatory rim of microglia and/or macrophages. 
The chronic inactive lesions are solely defined by a hypocellular centre.  
A more recent classification distinguishes between early active, late active and inactive lesions. 
Early active lesions are characterized by the presence of macrophages, expressing myeloid 
related protein 14 and containing myelin degradation products such as myelin-associated 
glycoprotein, myelin oligodendrocyte protein (MOG), myelin basis protein (MBP), myelin 
proteolipid protein (PLP) and cyclic nucleotide phosphodiesterase. Late active lesions are only 
positive for MOG and PLP. In contrast, no degradations products are present in inactive lesions 
43. T cell infiltrations are mostly located perivascularly and parenchymally. 
Four different patterns of active lesions are described in MS patients: 
 
MS Pattern I demyelination is characterized by massive T cell and macrophage infiltration. 
Pattern II shows additional immunoglobulin and complement deposition. 
Pattern III is also characterized by immune cell infiltrates and the absence of immunoglobulin 
and complement deposition. In contrast to Pattern I, oligodendrocyte apoptosis is observed in 
MS pattern III. 
The MS Pattern IV is very rare, but known to show a T cell and macrophage infiltration without 
immunoglobulin or complement deposition except for the non-apoptotic degeneration of 
oligodendrocytes35. 
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1.1.6. Current MS therapies 
Current treatment strategies for patients with RRMS can be divided in disease modulatory 
treatment (DMT) and treatment during acute relapses. The choice of the DMT depends on the 
disease activity and the risk-benefit profile of the drug. 
As first line therapies for RRMS patients with mild disease activity, glatiramer acetate (GA), IFNβ, 
teriflunomide and dimethyl fumarate (DMF) are most widely used. 
IFNβ and GA are injectable therapeutics whereas teriflunomide and DMF are oral medications. 
These four first line therapies are moderate immune modulators and show a good benefit-risk 
profile. Reduction of the relapse rate and a decreased development of new MRI lesions are 
reported44–49.  
In order to switch from a first line DMT to a second line treatment, RRMS patients must be 
diagnosed with at least two disabling relapses within the last year. As a second line therapy, 
monoclonal antibodies such as natalizumab and alemtuzumab or oral treatments such as 
fingolimod are used. These medications show a significantly higher therapeutic efficacy 
compared to first line DMT. MRI activity, relapse rate and disability scores were highly decreased 
after these medications50–52. Although natalizumab is beneficial in MS, it also elevates the risk of 
patients to develop progressive multifocal leukoencephalopathy (PML)53,54. If these treatment 
options are not successful in controlling disease activity, further therapeutic options are 
available such as daclizumab, mitoxantrone and rituximab55–57. Daclizumab and rituximab are 
monoclonal antibodies and are known to reduce relapse rate in RRMS patients. Mitoxantrone is 
an immunosuppressive drug and shows a reduction of relapse rate and disease symptoms in 
RRMS patients 57.  
 
During acute relapses, the standard medication is a daily, high dosage, intravenous application 
of corticosteroids for 3-5 days58. Secondary treatment options are immunoadsorption or plasma 
exchange for patients which show an incomplete recovery after steroid treatment59,60. 
 
In progressive disease forms of MS (PMS), most of the immunomodulatory drugs failed to 
control disease activity61. Mitoxantrone treatment is known to reduce relapse in SPMS but does 
not affect the continuous progressive process62,63. Due to the limited success of 
immunomodulatory drugs, other therapeutic approaches may be more successful. However, the 
incomplete understanding of the pathogenesis of PMS complicates the development of new 
drugs. At the moment, a broad number of new therapeutics are under investigations. In the MS 
SMART trial three neuroprotective-drugs (amiloride, riluzole, fluoxetine) are investigated for 
their efficacy in SPMS64. 
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1.1.7. B cell depleting therapy 
In the last decades, B cell therapies came into the focus of MS research, which was initiated by 
the finding that B cell depletion causes rapid clinical benefit in MS patients34. 
Rituximab is a chimeric mouse-human monoclonal IgG1 antibody directed against CD20, a 
lineage marker of B cells. CD20 expression starts at the late pre B cell development and it is 
present on pre, immature, mature and memory B cells, but not on CD138+ plasma cells (figure 
2)65. Therefore, an antibody directed against CD20 affects all B cell stages except very early B 
cells and plasma cells. It is used since 1994 to treat non-Hodgkin’s lymphoma (NHL), chronic 
lymphocytic leukemia (CLL), rheumatoid arthritis (RA) and lupus nephritis66–69.  
 
 
Figure 2 Development of surface lineage marker on B cells. 
Expression of CD19, CD20 and CD138 in different stages of B cell development. 
 
The efficiency of rituximab has been shown in various clinical trials. In 2008, a small study with 
RRMS patients was published which shows a significant reduction of gadolinium enhanced 
lesions after 2 courses of rituximab treatment. Lesion load was significantly reduced. This effect 
was observed until 48 weeks after the first dosage of rituximab34. In a phase II clinical trial with 
PPMS patients, rituximab could not reduce the EDSS score. Hence, rituximab may not affect 
progressive forms of MS70. 
Described side effects are related to a reaction after the first injection, which are rashes, 
itchiness, lowered blood pressure and a shortness of breath. However, the following infusion is 
usually much better tolerated71. 
 
Another therapeutic antibody targeting CD20 is the humanized monoclonal antibody 
ocrelizumab that binds to a different but overlapping epitope such as rituximab. Due to the more 
humanized form of ocrelizumab, it is thought to induce less of an immune response to foreign 
antigens and shows a higher binding ability to the CD20 molecule. The depleting mechanism in 
contrast to rituximab is mediated mainly over the antibody-dependent cell- mediated 
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cytotoxicity (two to fivefold higher compared to rituximab) than over complement induced 
cytotoxicity (three to fivefold lower compared to rituximab)55,72. 
In a phase III trial of ocrelizumab vs Interferon beta, ocrelizumab showed a reduction of relapse 
rate (46-47%), gadolinium enhanced T1 lesions (94-95%) compared to trial beginning and 
disability rate (40% compared to IFN-beta) in RRMS patients73. 
 
Ofatumumab is a completely humanized monoclonal aCD20 antibody which is approved for 
chronic lymphocytic leukemia. Ofamutumab, which binds to a different epitope than 
ocrelizumab and rituximab, mediates B cell depletion over antibody-depend cytotoxicity and 
complement activation. The first Phase II trial in RRMS patients showed a relative reduction of 
gadolinium enhanced T1 and T2 lesions up to 99% after infusion74. No side effects were 
described in the Phase II trial. Currently, further studies are planned. 
 
1.1.7.1. Mechanism of aCD20 antibody mediated depletion 
The effective depletion of B cells by rituximab is mediated by two different pathways after 
binding of the antibody to CD20: complement induced cytotoxicity (CDC), antibody-dependent 
cell-mediated cytotoxicity (ADCC). 
 
The main route of B cell depletion by rituximab is via the activation of the complement system. 
It consists of different ≥30kDA plasma proteins which become activated after antibody binding, 
resulting in the formation of the membrane attack complex (MAC) leading to the lysis of the cell 
membrane. The complement cascade can be triggered by different pathways. Rituximab is 
known to trigger the classical pathway. In this pathway, the C1b complement protein binds to 
the Fcƴ region of the antibody and the cascade is activated, leading to the insertion of the MAC 
into the cell membrane of the CD20+ B cells resulting in cytolysis75. 
 
The second pathway, by which rituximab mediates B cell depletion is via antibody-dependent 
cell-mediated cytotoxicity (ADCC). Monocytes/macrophages, granulocytes and natural killer 
cells can bind the Fc region of ocrelizumab, three- to fivefold higher than rituximab, via their Fc-
receptor. This leads to the cross-linking of Fc receptors, triggering degranulation of cytotoxic 
substances into a lytic synapse and subsequent apoptosis of the bound B cell76. 
 
 




Figure 3: Mechanism of rituximab. 
a) complement mediated cytotoxicity b) antibody-dependent cell-mediated cytotoxicity (adapted 
and modified from Jagadesh et al77). 
 
  




1.2. Experimental autoimmune disease (EAE) 
 
1.2.1. Pathogenesis of EAE 
EAE was first described in 1933 and is one of the most common and best described animal 
models for MS reflecting the inflammatory side of MS78.  
EAE can be induced by “active immunization” in different animals, primary in rodents and 
primates. “Active immunization” is conducted with a myelin sheath protein or peptide, e.g. MBP, 
PLP or MOG. The clinical outcome and progression based on the choice of species and used 
protein for EAE induction. 
In mice, the most common immunization protein is MOG. Here, the peptide with the amino acid 
sequence p35-55 (MOG p35-55) emulsified in CFA (Complete Freund’s adjuvants) is most widely 
used79,80. 
In the MOG p35-55, induced EAE Th1 and Th17 are thought to be the effector cells. First 
pathogenic effect of IFNβ releasing Th1 cells were described81. Adaptive transfer of these Th1 
cells induced EAE82. IL-12 is a central cytokine for the differentiation of Th1 cells, but 
interestingly, IL-12-deficient mice are still susceptible to EAE induction83. Furthermore, transfer 
of pathogenic Th17 cells cause EAE induction82,84. However, none of the single cell types is 
essential for EAE induction. 
Another important effector cell type are the anti-inflammatory regulatory T cells. Regulatory T 
cells are reported to inhibit the differentiation of autoimmune T cells. Adoptive transfer of these 
IL-10 producing T cells can also inhibit EAE induction85–87. During the course of EAE, regulatory T 
cells are essential for the recovery phase88. 
MOG p35-55 immunization leads to the introduction of antigen on B cells or macrophages on 
their surface via the MHCII molecule to activated T cells89–91. After migration into the CNS, the 
autoreactive T cells are reactivated by local or infiltrating APCs which present myelin fragments 
and can then mediate a breakdown of the BBB92,93. This reactivation induces further 
inflammatory processes which lead to demyelination and axonal damage90,94. Interestingly, 
Weber et al.95 described in 2010 a clinical worsening after B cell depletion in MOG p35-55 
immunized mice which led to the hypothesis that MOG p35-55 induced EAE is T cell mediated 
and most of the B cells seems to have a regulatory function.  
It is also possible to induce EAE by injecting the complete recombinant murine MOG protein 
(rMOG 1-117), emulsified with CFA in mice. In contrast to MOG p35-55 EAE, the rMOG protein 
needs to be internalized, processed and presented by APC, especially B cells, to activate T cells91. 
This induces the generation of antigen specific B cells. These antigen-activated B cells produce 
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MOG-specific antibodies96. Here, the EAE , in contrast to “T cell mediated” MOG p35-55 induced 
EAE, is B cell and T cell mediated and B cell depletion causes clinical worsening95. A third 
opportunity to induce EAE by MOG protein is to use human MOG protein (hMOG), which induces 
a B cells dependent EAE. Lyons et al.97 show that B cell deficient mice are not able to develop 
hMOG induced EAE but MOG p35-55 induced EAE. 
1.2.2. B cell function EAE 
Several studies show the contradictory role of B cells. On the one hand, B cell deficient mice 
developed a more serve EAE without remission98–100. On the other hand, the release of 
autoimmune MOG specific antibodies enhanced demyelination and inflammation97,101. In 
addition, B cells may have an essential role in EAE as antigen presenting cells (APC)80,102. This 
dichotomy of B cell functions is due to a variety of B cell functions in different B cell subsets. 
 
1.2.2.1. B cells differentiate into plasma cells and release autoimmune antibodies 
After antigen recognition, B cells can differentiate into memory B cells and CD138+ plasma cells 
which are able to generate antibodies against specific antigens. When these specific antibodies 
target their antigen, the complement system is activated. 
Similar to MS lesions where myelin sheath specific antibodies are found in areas with massive 




Figure 4: Schematic overview of B cell function. 
Figure 1.2.1: Schematic overview of B cell function. a) cytokine secretion/regulation b) APC 
function and co-stimulation and c) antibody production (adapted from Lehmann-Horn et al., 
2013104). 
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1.2.2.2. B cells act as antigen presenting cells 
In the periphery, many different professional APCs are well studied, including dendritic cells 
(DC), monocytes/macrophages and B cells. Furthermore, in the CNS antigen presentation plays 
a major role for reactivating infiltrating T cells. Two different types of APCs are known, the 
resident APCs, including astrocytes and microglia and the non-resident APCs such as B cells, 
macrophages/monocytes and dendritic cells, which play an important role in EAE105,106. 
Different APCs are known to be essential for EAE induction. This was shown by Greter et al.107 in 
2005 for DCs. MHCII restricted antigen presentation by DC was shown to be sufficient to induce 
EAE. For B cells, it is reported that in complete protein EAE they are necessary as professional 
APCs. After internalization of complete MOG protein B cells act as superior APCs. The antigen 
presentation to CD4+ T cells via the B cell receptor (BCR) is 10.000 times better compared to the 
unspecific antigen uptake of T cells108. In comparison to DCs, which are more specialized to 
present peptides, antigen specific B cells are more efficient in processing and presenting protein 
antigens which they have recognized with their BCR108–110. 
The BCR recognizes complete proteins and after internalization and processing, the resulting 
peptides are presented on MHCII molecules and the B cell up regulates costimulatory molecules 
such as CD40, CD80 and CD8637.  
In 2013, Molnarfi et al.111 reported that B-cellMHC II-/-mice were resistant to EAE induced by 
recombinant human MOG protein. They conclude that MHCII-dependent antigen presentation 
by B cells is necessary for EAE induction. 
 
1.2.2.3. B cells secrete pro- and anti-inflammatory cytokines 
The dichotomy of B cell function becomes clear by facing the distinct cytokine profile of B cells. 
B cells are able to produce pro- as well as anti-inflammatory cytokines. One of the most 
important pro-inflammatory cytokines in EAE is IL-6 which induces generation of 
encephalitogenic Th17 cells39. IL-6 deficient mice are reported to be completely resistant to 
EAE112. This becomes more clearer in another study where IL-6 deficiency is restricted to B cells. 
Mice in this which IL-6 deficiency is restricted to B cells develop a milder EAE progression while 
this effect is no longer observed after transfer of wild type B cell which were able to produce IL-
6112. 
Lymphotoxin-alpha (LT-α) and tumor necrosis factor alpha (TNFα) are also pro-inflammatory 
cytokines secreted by B cells in MS40. 
In contrast, B cells can secrete anti-inflammatory cytokines such as IL-10 and IL-35. IL-10 
deficient mice are not able to recover from EAE. Even after a transfer of IL-10-competent B cells, 
mice do not fully recover from relapses99.  
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Inhibition of the secretion of IL-10 or IL-35 in B cells increases the disease severity and prevents 
physiological recovery from an acute disease relapse113. 
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Table 1: Reagents 
Reagents  SOURCES OF SUPPLY  
Acetic Acid  Merck Millipore, Germany  
Agarose  Starlab GmbH, Germany  
BD FACS Clean™  BD Biosciences, USA  
BD FACS Flow™  BD Biosciences, USA  
BD FACS Rinse™  BD Biosciences, USA  
BD FACS™ Lysing Solution, 10x  BD Biosciences, USA  
BD Pharm Lyse™, 10x  BD Biosciences, , USA  
Boric Acid  Merck Millipore, Germany  
Crystal Violet  Sigma Aldrich, USA  
Cytofix/Cytoperm™  BD Biosciences, , USA  
Cytofix™  BD Biosciences, USA  
Chloral Hydrate  Merck Millipore, Germany  
Citric Acid  Merck Millipore, Germany  
DAB (3,3’-Diaminobenzidine)  Sigma-Aldrich Chemie GmbH, Germany  
DDSA (2-Dodecenylsuccinic Acid 
Anhydride)  
Serva Electrophoresis GmbH, Germany  
DEPEX  VWR International, Germany  
DMSO (Dimethyl Sulfoxide)  Sigma Aldrich, USA  
EDTA (Ethylenediamine Tetraacetic Acid 
Disodiumsalt Dihydrate)  
Carl Roth, Germany  
Ethanol, 100%  Merck Millipore, Germany  
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Ethidium Bromide  Sigma Aldrich, USA  
Eosin G  Merck Millipore, Germany  
FCS (Fetal Calf Serum)  Sigma Aldrich, USA  
Generuler™, 100 Base Pairs (bp) DNA 
Ladder Plus  
ThermoFisher Scientific, USA  
Go-Taq® DNA Polymerase Buffer, 5x  Promega, USA  
HCl (Hydrochloric Acid)  Merck Millipore, Germany  
H2O2 (Hydroxic Peroxide), 30%  Merck Millipore, Germany  
Isopropyl Alcohol  Merck Millipore, Germany  
L-Glutamine, 200 Mm  Sigma Aldrich, USA  
LPS (Lipopolysaccharide)  Sigma Aldrich, USA  
Mayer’s Hemalum  Merck Millipore, Germany  
NaCO3 (sodium carbonate)  Merck Millipore, Germany  
NaHCO3 (sodium hydrogen carbonat)  Merck Millipore, Germany  
NaF (sodium fluoride)  Merck Millipore, Germany  
PBS (Phosphate Buffered Saline), 10x  Biochrom AG, Germany  
PBS (Phosphate Buffered Salt Solution), 
Sterile  
Sigma Aldrich, USA  
Penicillin, 10,000 Units  Sigma Aldrich, USA  
Perm/Wash™ Buffer, 10x  BD Biosciences, USA  
PFA (Paraformaldehyde), Powder  Merck Millipore, Germany  
PMA (Phorbol 12-Myristate 13-Acetate)  Sigma Aldrich, USA  
RPMI-1640 (Roswell Park Memorial 
Institute-1640)  
Sigma Aldrich, USA  
Sodium Pyruvate, 100 mM  Sigma Aldrich, USA  
TMB (3,3’,5,5’-Tetramethylbenzidine) 
Substrate Solution  
Ebioscience, USA  





Carl Roth, Germany  
Trypan Blue  Sigma Aldrich, USA  
Tween  Merck Millipore, Germany  




Table 2:Solutions, buffers and cell culture media 
Solutions, buffers and cell culture media  COMPOSITION  
Blocking Buffer for Immunohistochemistry  PBS  
  10% FCS  
CFA (Complete Freund’s Adjuvant)  Paraffin oil  
  15% mannide monooleate  
  6.7 mg/ml Mycobacterium tuberculosis H37RA  
Citric Acid Buffer, 10 Mm  2.1 g citric acid  
  1 l distilled water  
  NaOH, adjust to pH 6  
Coating buffer  8.4 g NaHCO3  
  3.5 g NaCO3  
  1 l distilled water  
  Stir filter, adjust to pH 9.5  
3,3’-Diaminobenzidine Tetrachloride (Dab) 
Working Solution  
PBS  
  0.5 mg/ml DAB  
  
add 20 μl 30% hydrogen peroxidase per 50 ml 
DAB solution before use  
ELISA wash buffer  200 ml 10x PBS  
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  1 ml Tween  
  1.8 l distilled water  
ELISA stop solution  1 N H2 SO4 solution  
1% Eosin  70% isopropyl alcohol  
  1% eosin G  
  stir filter, before use add 0,5% acetic acid  
(Fluorescence-Activated Cell Sorting) Buffer  PBS, sterile  
  2% FCS  
1% HCl  1% HCl absolute  
  70% ethanol  
MACS (Magnetic-Activated Cell Sorting) Buffer  PBS, sterile  
  0.5% FCS  
  2 mM EDTA  
  pH 7.2  
Neutralization buffer  40 mM Tris  
  250 ml distilled water  
10x PBS  95.5 g PBS  
  1 l distilled water  
RD1 buffer (ELISA block buffer)  200 ml 10x PBS  
  20 g BSA  
  1.8 l distilled water  
RPMIcomplete  RPMI-1640  
  10% FCS  
  1 mM sodium pyruvate  
  2. Material and Methods 
18 
 
  50 μM β-Mercaptoethanol  
  100 units penicillin  
  2 mM L-glutamine  
TAE (Tris, acetic acid, EDTA) buffer  40 mM Tris  
  20 mM acetic acid  
  1 mM EDTA  
  1 l distilled water (adjusted to pH 8)  
Tail lysis buffer  25 mM NaOH  
  2 mM EDTA  
  250 ml distilled water  
2.1.3. Protein enzymes and inhibitors 
Table 3:Proteins, enzymes and inhibitors 
Proteins, enzymes and inhibitors  SOURCE OF SUPPLY  
BSA (bovine serum albumin)  SERVA Electrophoresis GmbH, Germany  
Recombinant mouse MOG-protein1-117  Monash University, Australia  
PTX (pertussis toxin)  List biological laboratories, USA  
DNase I  Roche, Basel, Switzerland  
Dreamtaq green PCR master mix (2x)  Thermo Fisher Scientific, USA  
MOG p35-55 peptid Auspep, Austria 
Proteinase K  Sigma Aldrich, USA  
Trypsin, 0.05%  Gibco/Invitrogen, USA  
2.1.4. Monoclonal antibodies for flowcytometry 
Table 4: Monoclonal antibodies for flow cytometry 
Monoclonal 
antibodies for 
flow cytometry  
FLUOROCHROM
E  
CLONE  DILUTION  
SOURCE OF 
SUPPLY  
B220  FITC  RA3-6B2  1:100 BioLegend  
B220  PE-Cy7  RA3-6B2  1:100 BD Biosciences  
CD1D  Pacific Blue  1B1  1:100 BioLegend  
CD4  BV510  GK1.5  1:100 BioLegend  
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CD4  PE  RM4-5  1:100 BioLegend  
CD5  PerCP-Cy5.5  53-7.3  1:100 BioLegend  
CD8a  FITC  53-6.7  1:100 BioLegend  
CD19  APC-Cy7  6D5  1:100 BioLegend  
CD20 AlexaFlour 488 SA275A11 1:200 BioLegend  
CD23  APC  B3B4  1:100 BioLegend  
CD27  FITC  LG.3A10  1:100 BioLegend  
CD37  PE  Duno85  1:100 BioLegend  
CD38  Pacific Blue  90 1:100 BioLegend  
CD69  PerCP-Cy5.5  H1.2F3  1:100 BD Biosciences  
CD80  APC  16-10A1  1:100 BD Biosciences  
CD86  PE  GL1  1:100 BD Biosciences  
CD95 (FAs)  PE  Jo2  1:100 BD Biosciences  
CD138  PE  281-2  1:100 BioLegend  
GL-7  FITC  GL7  1:100 BioLegend  
IFNΓ  APC  XMG1.2  1:100 BioLegend  
IgM  FITC  RMM-1  1:100 BioLegend  
IgD  PE  11-26c.2a  1:100 BD Biosciences  
MHC-II  Pacific Blue  AF6-120.1  1:200 BioLegend  
 
 
2.1.5. Monoclonal antibodies for antigen independent activation in vitro 
Table 5: Monoclonal antibodies for antigen-independent activation of T cells in vitro 
Monoclonal antibodies for antigen-independent 
activation of T cells in vitro  
CLONE  SOURCE OF SUPPLY  
LEAF™ purified anti-mouse CD3  145-2C11  BioLegend  
LEAF™ purified anti-mouse CD28  37.51  BioLegend  
 
2.1.6. Primary antibodies for immunohistochemical staining 













B220  rat  
microwave, citric 
acid buffer  
1:200 BD Pharmingen  
CD3  rat/ CD3-12  
microwave, citric 
acid buffer  
1:200 Biorad  
MAC3  Rat/ M3/84  
microwave, citric 
acid buffer  
1:200 BD Pharmingen  
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2.1.7. Secodary antibodies for immunohistochemical staining 
Table 7: Secondary antibodies for immunohistochemical staining 
Secondary antibodies for 
immunohistochemical staining  
DILUTION  MANUFACTURER  
Anti-mouse IgG, biotinylated  1:200 
GE Healthcare Europe GmbH, 
Germany  
Anti-rabbit IgG, biotinylated  1:200 
GE Healthcare Europe GmbH, 
Germany  
Anti-rat IgG, biotinylated  1:200 
GE Healthcare Europe GmbH, 
Germany  
 
2.1.8. Applied Kits 
Table 8: Applied Kits 
Applied Kits  SOURCE OF SUPPLY  
CD4+ T cell isolation kit II, mouse  Miltenyi Biotec, Germany  
Cell lineage panel kit, mouse  Miltenyi Biotec, Germany  
Dylight 405 Antibody labeling Kit  Thermo Fisher Scientific, USA  
BD Pharmingen™ BrdU Flow Kits, FITC BD Biosciences 
 
2.1.9. Primers 
Table 9: Primers 
Primers  SEQUENCE  SOURCE OF SUPPLY  
Ja18-2D2  
5’-CCC GGG CAA GGC TCA GCC 
ATG CTC CTG-3’  
Eurofins Scientific, Germany  
Va3-2-2D2-M  
5’-GCG GCC GCA ATT CCC AGA 
GAC ATC CCT CC-3’  
Eurofins Scientific, Germany  
 
2.1.10. Consumables 
Table 10: Consumables 
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Consumables  SOURCE OF SUPPLY  
Bottle Top Filter, 0.2 μm  Sarstedt, Germany  
Cell Culture Plates, Flat Bottom (6 Well, 24 Well, 
96 Well)  
Greiner bio-one, Austria  
Cell Strainer (70 μm)  Greiner bio-one, Austria  
FACS Tube, 5 ml  Sarstedt, Germany  
LS Columns  Miltenyi Biotec, Germany  
Needles  BD Biosciences, USA  
Nunc™ Maxisorp® 96 Well ELISA Plate  Thermo Scientific, USA  
96 Well Plate Round  Sarstedt, Germany  
Pre-Separation Filters, 30 μm  Miltenyi Biotec, Germany  
Syringes  BD Biosciences, USA  
Tubes (50 ml, 15 ml, 10 ml, 2 ml, 1,5 ml,  Sarstedt, Germany  
0.2 ml)    
 
2.1.11. Technical devices 
Table 11:Technical devices 
Technical devices  SOURCE OF SUPPLY  
Bx51 Olympus light microscope equipped with 
DP71 digital and XM10 monochrome camera  
Olympus, Germany  
Centrifuge 5415 R  Eppendorf, Germany  
Centrifuge 5810 R  Eppendorf, Germany  
FACS LSR II  BD Biosciences, USA  
Cell Incubator BBD6220  Thermo Scientific, USA  
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IMARK™ Microplate Reader  Bio-Rad, Germany  
Microscope  Olympus  
Microtome  Leica, Germany  
Microwave  Bosch, Germany  
Neubauer Chamber  Superior Marienfeld , Germany  
QuadroMACS™ Separator  Miltenyi Biotec, Germany  
T3 Thermocycler  Biometra, Germany  
 
2.1.12. Software 
Table 12: Software 
Software  APPLICATION  SOURCE OF SUPPLY  
BD biosciences FACSDiva 
software 6.1.2  
Data acquisition flow 
cytometry  
BD Biosciences, USA  
FlowJo 10.1  Data analysis flow cytometry  Tree Star Inc., USA  
GraphpadPrism 6  Statistical analysis and Graphs GraphPad software Inc., USA  
ImageJ 1.47d  Data analysis histology  
National Institutes of Health, 
USA  
PSremote 1.6.5  Gel documentation  Breeze systems limited, UK  
 
  





C57BL/6 mice were purchased from Charles River (Sulzfeld, Germany). Animals were used at 6-
8 weeks of age.  
 
2D2 mice express the MOG35-55-specific T cell receptor Vα3.2/ Vβ11 on CD4+ T cells. In 
2003, Bettelli et al. generated and characterized 2D2 animals114. 2D2 CD4+ T cells were used 
in co-culture experiments. Mice breeding was performed in the animal facility in university 
medical center Göttingen. 
 
2.2. Methods 
2.2.1. Genotyping of genetically modified mice of 2D2 
For the genotyping of 2D2 mice, tissue was obtained via a tail biopsy. Afterwards DNA was 
extracted and amplified with specific primers and PCR products were separated by 
agarose gel electrophoresis as described below. 
DNA extraction  
DNA was isolated from the tissue gained by the tail biopsies of 2D2 mice. The tissue was digested 
in 100 μl of lysis buffer at 99°C for 30 min. Afterwards, 100 μl of neutralization buffer was added. 
  
PCR reaction  
Each reaction sample contained 1 μl of genomic DNA, 10 μl of Dream Taq® PCR Mix 2x, 1 μl of 
each primer and 7 μl of water (nuclease free).  
Primer 1: 5’-CCC GGG CAA GGC TCA GCC ATG CTC CTG-3’  
Primer 2: 5’-GCG GCC GCA ATT CCC AGA GAC ATC CCT CC-3’  
 
PCR conditions  
• Initial denaturation: 94°C, 2 min  
• 35 cycles: Denaturation: 94°C, 1 min  
Annealing: 58°C, 1 min  
Extension: 72°C, 1 min  
• Final extension: 72°C, 10 min  
 
Agarose gel electrophoresis  
5 μl of PCR product was loaded on an agarose gel (2% (w/v) in TAE buffer) containing 3 μl 
of ethidium bromide/GelRed. Electrophoresis was performed in a Sub‐Cell GT Agarose Gel 
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Electrophoresis System at 120V for 45 min. Gel-documentation by UV-light was used for 
evaluation of PCR products. 
2.2.2. B cell depletion by aCD20 treatment 
Preventive B cell depletion in C57Bl6/j mice was achieved by three intraperitoneal (i.p.) 
injections once a week of 200 µg of murine aCD20 IgG monoclonal antibody (provided by 
Roche) solved in 200 µl of PBS. As a control group, C57Bl6/j mice were treated with an 
RAG weed isotype control antibody which has the same IgG isotype as the aCD20 
antibody. B cell depletion or control treatment were performed preventively 3 weeks 
before analyzing in naive mice or 3 weeks before immunization in both EAE models 
described below. 
2.2.3. Experimental autoimmune encephalomyelitis  
After treatment with aCD20 or control Ab, T cell mediated EAE was induced by 100 µg of MOG 
p35-55 injected subcutaneously (s.c.) and 300ng Pertussis toxin (PTX). PTX injection was 
repeated after 48h. The B cell mediated EAE was induced by using 75µg recombinant MOG 
protein 1-117 (kindly provided by C.A. Bernard and synthesized, purified and refolded as 
previously reported) subcutaneously and two injections of 300ng PTX. 
 
2.2.4. Clinical EAE score  
To assess EAE severity, body weight and disease scores were evaluated daily in each animal from 
day ten after immunization until the end of the experiment. The criteria defining the clinical EAE 
score used in this study are summarized in Table 13. Animals reaching a disease score of 4 had 
to be sacrificed, due to ethical reasons. 
Table 13: EAE Score 
EAE Score Clinical signs 
0 no clinical disease 
1 tail weakness 
2 hind limb weakness 
3 one paralyzed hind limb 
4 two paralyzed hind limbs 
5 moribund or dead animals 
 
 
2.2.5. Preparation of a single cell suspension for characterization of remaining and 
reappearing B- and T cells 
For characterizing of remaining and reappearing B cells after aCD20 depletion, mice were 
treated with aCD20 or control antibodies described in part 2.2.1.2.. For experiments 
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characterizing remaining and reappearing B and T cells mice were scarified at different time 
points after preventive depletion or control treatment. Single cell suspension of peripheral 
organs were prepared described in the following parts. Each experiment was repeated at least 
two times with n=2-4 animals per group and time points.  
2.2.5.1. Preparation of lymphocytes suspension from spleen, lymph node and bone marrow 
Single cell suspensions were prepared from spleen, lymph node and blood for further analysis. 
All centrifugation steps were performed for 10 min at 300 xg and 4°C and cells were washed in 
10 ml of PBS, if not stated otherwise. 
Tibia and femur of one hind leg were flushed with ice cold PBS to isolate bone marrow. Single 
cell-suspension of bone marrow was prepared by flushing the suspension through a 70µm cell 
strainer. Spleen and lymph node were disrupted over a 70µm cell strainer to prepare single cell 
suspension. Single cell suspensions of all investigated compartments were washed two times for 
10 min at 300xg at 4°C. 
2.2.5.2. Preparation of blood cells 
50µl blood was collected in 300µl 0.1mM EDTA buffer to avoid aggregation. Blood was 
centrifuged at 1400rpm for 5min. Pellet was solved in 500µl Pharm LyseTM solution (1:10) for 
lysis of erythrocytes in the blood for 3min. Lysis was stopped with 1ml FACS buffer (PBS, 2% FCS). 
Cell suspension was washed two times. 
2.2.5.3. FACS staining procedures 
Single cell suspension was washed and centrifuged in FACS buffer. Afterwards 200µl of single 
cell suspension were added per well in a 96-well plate. Cells were centrifuged and washed with 
FACS buffer. Cells were resuspended in 30 μl blocking buffer, consisting of anti-CD16/CD32 
antibody diluted 1:100 in FACS buffer, then incubated for 5 min at 4°C. Fluorochrome-labelled 
antibodies were diluted 1:50 in FACS buffer. 50 μl of this antibody mix were added to each well 
which lead to a final concentration of 1:100. A 96-well plate was incubated for 15 min on ice in 
the dark. After incubation, single wells were filled with 140 μl of FACS buffer and the plate was 
centrifuged. Cells were washed and resuspended then washed again with 200 μl of FACS. Cells 
were resuspended in 100µl of FACS buffer and 100µl of 4% PFA solution was added at each well 
(final concentration: 2% PFA) to fixate cells. After 20 min, incubation cells were centrifuged and 
washed with 200µl of FACS buffer. Finally, cells were stored in 200µl of FACS buffer. Fixed cells 
were analysed by flow cytometry with BD Fortessa LSR. 
 
  2. Material and Methods 
26 
 
2.2.5.3. Cell counting 
The Neubauer chamber was used for the determination of cell numbers. The cell suspension 
was diluted 1:10 in trypan blue (diluted 1:10 in PBS) to exclude dead cells prior to counting. After 
counting four squares, the concentration of cells in the original sample was calculated by the 
following formula:  
 
Cells counted/4 * 10 * 104 = cells/ml  
The total cell number was extrapolated to the sample volume. 
2.2.6. Characterization of B cells and T cells after aCD20 treatment 
For the characterization of C57Bl6/j mice after treatment with aCD20 antibody or control 
antibody in EAE models or naïve mice, mice were sacrificed weekly after 0-14 weeks after the 
last aCD20 treatment. Single cell suspensions of spleen, lymph node, bone marrow and blood 
were prepared as described above. 
2.2.6.1. Phenotyping of reappearing B cells in EAE 
B cell depleted or control antibody treated immunized mice were sacrificed after 8 and 12 weeks 
after the last treatment. Here, single cell suspensions of splenocytes were stained by following 
antibody panels by FACS. 
Table 14: B cell phenotyping 
B cell phenotype Surface marker 
Naive B cells CD23-, IgM+, IgD- P 
Mature B cells  CD23+, CD38+, IgM-, IgD+ 
Memory B cells B220high, CD38+, IgD-  
Regulatory B cells CD1dhigh, CD5+  
Germinal center cells 
CD37+, GL7+ 
Activated B cells CD27+, CD69+, CD80+,  
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2.2.7. Co-culture experiments 
2.2.7.1. Isolation of B cells and MOG-specific T cells 
Splenocytes were isolated as described above in 2.2.5.1.. B cells and T cells were isolated by 
magnetic associated cell sorting (MACS). Single cell suspension of the spleen was washed two 
times with MACS buffer and treated according to the manufacturer’s instructions. B cells were 
sorted negatively by using Lineage panel (mouse, BD). T cells were purified using the CD4+ T cell 
isolation kit II (mouse, BD). Afterwards, the LS columns and the QuadroMACSTM separator were 
used to isolate the specific cell population according to manufacturer’s instructions. Isolated B 
cells and T cells were used for co-culture or further experiments. 
2.2.7.2. CFSE staining of isolated T cells 
For analyzing T cell proliferation, T cells were stained with carboxyfluorescein succinimidyl ester 
(CFSE). CFSE can penetrate the intact cell membrane and binds irreversibly to intracellular 
proteins. At each cell division CFSE stained cytoplasma is halved. Due to this fact CFSE staining 
makes it possible to distinguish proliferation and their division status. Isolated T cells were 
counted and resuspended in 1ml PBS. 800µl of this cell suspension were incubated with 200µl 
CFSE solution (1:100, 5mM CFSE stock solution) for 10 min. Afterwards cell suspension was 
washed two times with RMPI complete. 
2.2.7.3. LPS/CpG stimulation of reappearing B cells ex vivo 
B cells of aCD20 or control antibody treated immunized mice were isolated 8 and 12 weeks after 
last aCD20 or control treatment as described in 2.2.3.1.. 200.00 B cells per well were plated in 
200µl RPMI complete. These isolated B cells were stimulated with 5 µg/m, 10µg/ml LPS or 
1µg/ml, 10µg/ml CpG overnight (18h). Supernatant was analyzed for released IL-6 and IL-10 by 
ELISA.  
2.2.7.4. MOG-Binding assay 
For analysing antigen-binding capacity, isolated reappearing B cells were incubated with 
fluorescence labelled rMOG protein for 2h at 37°C and 5% CO2. Labelling of rMOG protein 
was performed according to manufacturer’s instructions. After the incubation, B cells were 
washed with 200 μl FACS buffer, then resuspended in 200 μl FACS buffer and immediately 
analysed by flow cytometry. 
2.2.7.5. Co-culture of reappearing B cells and MOG specific T cells 
To investigate the APC function of reappearing B cells after aCD20 treatment, co-culture assays 
were performed. Preventively aCD20 or control treated mice of rMOG and MOG p35-55 EAE 
were sacrificed at week 7, 8, 12, 14 and 18 after last treatment. Single cell suspension of 
splenocytes was prepared as described in 2.2.5.1. and B cells were isolated by MACS separation 
(2.2.7.1). Further MOG specific T cells of 2D2 mice were isolated and stained with CFSE (2.2.7.2.). 
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500.000 isolated B cells were co-cultured with 20.000 MOG specific, CFSE stained T cells and 
plated in 96-well plate in 200µl of RPMI complete. Different concentrations of rMOG protein (0, 
5, 25, 50µg/ml) and MOG p-35-55 (0, 5, 25, 100 µg/ml) were used to re-stimulate the B cells 
according to their immunization. Cells were co-cultured for 72h at 37°C, 5%CO2, 95% humidity. 
Afterwards, supernatant was analyzed for IL-17, IL-2, IFN and IL-6 by ELISA. T cells were analyzed 
for proliferation rate by FACS. 
2.2.7.6. Stimulation of T cells during B cell repletion 
For investigating influence of aCD20 treatment on T cells during B cell repletion, T cells were 
isolated by MACS (s. 2.2.3.1.) and antigen independent stimulation with aCD3/aCD28 antibodies 
was performed. 96-U-buttom well plate was coated with different concentrations of aCD3 
antibody (0, 0.125, 0.25, 0.5, 1 µg/ml) and aCD28 antibody (10µg/ml) for 6-8h at room 
temperature. A 96-well plate was washed two times with 200µl PBS and 200µl of isolated CFSE 
stained T cells (1x106 cell/ml in RPMI complete) were added immediately. Cytokines in 
supernatant were measured by ELISA. Proliferation rate was analyzed by FACS. 
2.2.8. In vivo proliferation experiments 
2.2.8.1. In vivo proliferation of remaining B cells after aCD20 treatment  
Ten days after immunization of the preventively depleted or control treated Ab C57Bl6/j mice 
were injected intraperitoneally with 150µl of Bromodeoxyuridine (BrdU). BrdU is a synthetic 
nucleotide analog to thymidine and allows to investigate the proliferation of cells in vivo. BrdU 
was built into the DNA after cell division and proliferation can be determined. After 48h mice 
were sacrificed and spleen and lymph node were investigated for proliferating cells. Therefore, 
single cell suspension was prepared according to manufacturer’s instructions. Single cell 
suspension was stained for BrdU+ cells with an antibody against BrdU according to the 
manufacturer’s instructions.  
2.2.8.2. In vivo proliferation of reappearing B cells 8 weeks after aCD20 treatment 
For investigating the proliferation of B and T cells in spleen, lymph node and bone marrow of 
reappearing B cells 8 weeks after the last depletion, the same experimental setting as described 
in 2.2.8.1. was used. Instead of day 10 after immunization, BrdU was injected at day 52 (end 
week 7) and the proliferation was analyzed at week 8 (day 56).  
2.2.9. ELISA 
Cytokines of co- or single culture experiments and ex vivo stimulation were measured in 
supernatant by ELISA. The Mouse IFNγ or GM-CSF ELISA MAX™ standard set was used. 96-well 
plates were coated with 100µl of capture antibody solution (1:200 diluted in coating buffer). The 
next day, three washing steps were performed and then plates were blocked for 1h with RD1 
buffer at RT. Standard solutions were prepared according to the manufacturer’s instructions. 
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After three washing steps, 30µl of the sample were added and incubated over night at 4°C. Again 
three washing steps and antibody detection were performed (1:200 in RD1 buffer) and then 
incubated for 2h. Afterwards, three times of washing was performed and 100µl Avidin-HRP was 
added for 30 min. Subsequently, four washing steps were performed and 100µl of TMB was 
added until the colour changed into blue. After that, the colour change reaction was stopped by 
ELISA stop buffer. OD were determined by iMaikTM microplate reader at 450 nm with 540 nm 
wavelength correction. 
2.2.10. Histology 
2.2.10.1. Perfusion, tissue collection and sample preparation 
Mice were analyzed 14 weeks after the last aCD20/control treatment. Mice were sacrificed and 
perfusion was performed by punctuation of the left heart ventricle and flushing first by ice-cold 
PBS followed by 4%PFA for fixation. Brain, spinal cord, liver and spleen were collected in 4% PFA. 
After 2 days, PFA was replaced by PBS and stored for at least 24h. Brain was sliced in four 
transverse sections and spinal cord in 10-12 sections. 
 
Organ sections were watered and then gradually dehydrated overnight before paraffin 
embedding. This was done by an automated tissue processor which is performing a graded 
alcohol/xylene/paraffin series. Afterwards, paraffin blocks were sliced into 1µm thick slices by 
microtome and then laid on glass slides. 
Prior to any staining procedure, deparaffination and rehydration were performed in the 
following steps: 
4x 10 min xylol  
1x 5 min isoxylol  
2x 5 min 100% isopropyl alcohol (IPA)  
1x 5 min 90% isopropyl alcohol (IPA)  
1x 5 min 70% isopropyl alcohol (IPA)  
1x 5 min 50% isopropyl alcohol (IPA)  
Distilled water 
 
After finishing the staining procedure, the slices were dehydrated in reverse order. 
 
2.2.10.2. Luxol Fast Blue/Periodic Acid Schiff (LFB/PAS staining) 
LFB/PAS staining was performed to access demyelination in the CNS. Myelin was stained by LFB 
in blue by binding to lipoproteins, while PAS staining demyelinated areas in pink. After 
deparaffination and rehydration, slices were incubated overnight in LFB solution. The next day, 
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after washing the slices in 90% IPA, they were differentiated by dipping them into 0.05% lithium 
carbonate solution followed by a short dip into 70% IPA and a rinsing in dH2O. Then, slices were 
incubated with 1% periodic acid. Subsequently, slices were washed under tap water and dH2O. 
Slices were incubated in Schiffs’s solution for 20min and washed with tap water. 5 min of 
incubation with Mayer’s hemalaun were followed by differentiation in 1%HCl-alcohol (1%HCl-
alcohol in 90% isopropyl). The last step was washing the slices under tap water. Finally, the tissue 
was dehydrated and mounted in DePex medium. 
 
2.2.10.3. Immunohistochemical staining 
Visualization of signals was done by binding of avidin couples peroxidase (POX) and oxidation of 
DAB by POX in presence of H2O2. Different pre-treatments allowed enhancement of the signals. 
This included heating by microwave at 800W for 5x3min, acid (1mM citric acid or 1mM Tris-
EDTA) or proteinase treatment (10min, 37°C). After deparaffination, rehydration and pre-
treatment slices were washed 3x with dH2O. One further washing step with PBS was performed 
and slices were blocked with endogenous peroxidase to avoid unspecific signals. After rinsing 3x 
with hH2O pre-incubation with 10% FCS for 20 min, unspecific antigen-binding was reduced. 
Again slices were washed 3x times and then incubated with the primary antibody (diluted 10% 
FCS/PBS) overnight in a humidified chamber. Afterwards washing steps were performed 
followed by incubation with biotin conjugated secondary antibody (diluted in 10% FCS/PBS) for 
1h. The slides were rinsed with hH2O and then incubated in 0.1% POX for 1h. Signal development 
was performed by putting slices into DAB for several minutes and then rinsed immediately in 
PBS. Nuclei counterstaining was performed with Meyer’s hemalaun for 30sec followed by short 
washing with PBS. The differentiation was performed with 1% HCl-alcohol (1% HCl in 90% 
isopropyl alcohol). Rinsing slices with tap water was done for blueing of the tissue. The slices 
were dehydrated and mounted in DePex medium. 
 
2.2.11. Statistical analysis and data analyzation 
Flow cytometric data were evaluated with BDDivaTM and FlowJo 10.1 software. Statistics were 
calculated using the software GraphPad Prism 6. Unpaired t-test or Mann-Whitney-U test were 
used for all statistical comparison. A value of p<0.05 was considered as significant. Data are 
presented as mean ± SEM. 
  




3.1. Analysing depletion and repletion of B cells after aCD20 treatment 
 
3.1.1. Characterization of remaining B cells after aCD20 treatment 
Previous research has shown that B cell depletion is not completed by using aCD20 
treatment95. Small remaining B cell populations are still present in all immune relevant 
compartments. The goal of this study was to investigate the status of these remaining B cells 
and to understand the effect of B cell depletion by analysing B cell frequency in different 
immune relevant compartments.  
To investigate the efficiency of the aCD20 treatment, C57Bl6/j mice were treated with 0.2mg 
aCD20 monoclonal antibody or isotype control antibody (from now on referred to as control 
treated) three times. To analyse the number of B cells, a FACS staining with antibodies against 
B220, CD19, CD20 and CD27 was performed (figure 5). 
The results show that B220+ CD19+ B cell frequency was significantly reduced from 
59.53±1.58 % to 9.24±3.98 % upon aCD20 treatment in spleen (p<0.05). A similar reduction 
was measured in the lymph node from 33.52%± 1.32 B cells in the control treated group and 
7.22± 0.58 %in the aCD20 treated group (p<0.05). 
The most effective reduction of B cells was found in the blood. Here, the control group 
showed 41.25% to 50.40% B cells. After depletion with aCD20 Ab these B cell populations 
were significantly abolished (2.74±1.6%, p<0.005). In the bone marrow, a less effective, but 
still significant depletion of B220+CD19+ B cells was detectable. Here, aCD20 treatment 
reduced the B cells frequency from 28.2± 1.84% in the control group to 18.3± 1.84% in aCD20 
treated group (p<0.05). 
Due to this uncomplete depletion in the investigated compartments (figure 5), CD20 
expression of the remaining B cells after aCD20 treatment was analysed. In spleen, lymph 
and even in blood the remaining B cells show a CD20 expression from 97.3-99.8%, while in 
the bone marrow a non depletable CD20-population was detected (figure 5 b). This CD20- B 
cell population was also measured in the control group and 32.45±3.57% of the B cells in 
bone marrow are CD20- and not affected by CD20 antibody treatment. In bone marrow B cell 
development take place and CD20- precursor B cells are usually present. 
Further characterisation of the remaining B cell population showed an enrichment of CD27+ 
B cells which are defined as activated B cells upon aCD20 treatment in the spleen (figure 5 c). 
Especially in the spleen (remaining B cells 31.28±5.45% vs 13.14±2.19% ctrl treated B cells, 
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p<0.05) and in the lymph node (remaining B cells 21.57±3.03% vs 11.6±1.72% ctrl treated B 
cells, p<0.05) this enrichment was measured with a significantly higher amount of CD27+ 
activated B cells compared with in the control group (p<0.05). 
To investigate the localization and abundance of B cells in the spleen after treatment with 
aCD20 or control Ab, a histology was conducted. This histology stained with an antibody 
against B220 (figure 5 d) confirmed a reduction of B cells and revealed that the remaining B 
cells are located in the germinal centre structure. 
In summary, the remaining B cells in the spleen, the lymph node and the blood are CD20+, 
which means that they theoretically can be affected by the aCD20 Ab treatment. Here, the 
histology of aCD20 treated spleen revealed that the remaining B cells are possibly structurally 
protected against the aCD20 Ab. This hypothesis could also explain the high enrichment of 
CD27+ activated B cells which were mostly found in germinal centre structures.  




Figure 5: Characterization of B cells after aCD20 treatment. 
C57bl6/j mice were treated three times with 0.2 mg  of aCD20 or control Ab. a) 
shows representative FACS plots and frequencies of B220+ CD19+ B cells in spleen, 
lymph node, bone marrow and blood. b) shows the frequencies of remaining CD20+ 
B cells and c) the frequencies of CD27+B cells. d) representative sect ions of spleen 
from control or aCD20-treated mice are shown which were stained for B220+ cells. 
Means are shown of n=3 per group.  




3.1.2. B cell repletion in naïve mice 
MS patients treated with aCD20 Ab are monitored for the reappearance of B cells in the 
blood. To address the question whether the blood is the suitable monitoring compartment, 
we analysed the reappearance of B cells in naïve mice by FACS at several points of time in 
the spleen, the lymph node, the bone marrow and the blood. 
To investigate the repletion kinetic at different points in time after aCD20 treatment the B 
cell frequency of aCD20 treated and control treated mice were measured in different 
compartments. For each investigated time point the B cell frequency of control treated mice 
was set at 100% and B cell frequency of aCD20 treated mice was normalized to this value. 
The first evidence of reappearing B cells were observed in the spleen and the bone marrow 
after the last aCD20 treatment at week 7. This effect was not seen in the blood or in the 
lymph node at that time. In week 9 after the last treatment, B cells were also detected in the 
blood and the lymph node while reappearance of B cells was almost fully completed in the 
spleen and the bone marrow.  
Directly after three times of depletion, the CD19+B220+ B cell population is clearly depleted 
in all investigated compartments as described previously in this study. Even in week 4 after 
the last aCD20 treatment, no increase of the B cell population in all investigated 
compartments was observed. The first increase of B cells took place at week 7 after the last 
depletion while no increase of the B cell population was observed in any of the other 
compartments. In the bone marrow, a small increase was measured compared to control 
group. In contrast, the B cells in the blood were still fully depleted and B cells did not reappear 
until week 9 (figure 6). However, in all investigated compartments, the repletion was 
completed 12 weeks after last injection of aCD20 Ab. 
These results show that the B cell repletion in mice after aCD20 depletion is not equally 
distributed in all immune relevant compartments and B cell reappearance in blood and lymph 
node lacks behind compared to B cell reappearance in spleen and bone marrow. 




Figure 6: B cell repletion kinetic of naïve mice after aCD20 treatment. 
a) shows frequencies of CD19+ B220+ B cells in spleen, lymph node, bone marrow and blood 
of mice treated three times with 0.2 mg aCD20 Ab or isotype. Data are normalized to mice at 
the identical point in time. b) shows representative FACS plots of CD19+ B220+ B cells of 
control-treated mice and reappearing B cells in spleen, lymph node, bone marrow and blood 
of aCD20-treated mice during B cell repletion. Repletion kinetic shows means of two 
independent experiments with n=2 per group and point in time. 
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3.1.3. B cell repletion in the EAE models 
To assess whether blood is the optimal monitoring compartment for the reappearance of B 
cells and the consequence of reappearing B cells in patients with MS, two different EAE 
models were used. The first EAE model was induced by MOG p35-55, were EAE is T cell 
mediated. The second EAE model was induced by rMOG protein. In this model, B and T cells 
are actively involved in the disease progression. 
C57Bl6/j mice were preventively treated with aCD20 or control Ab three times and then 
immunized with MOG p35-55 or rMOG, both were additionally treated with pertussis toxin. 
During EAE course, the B cell frequency changes in the different compartments. Therefore, it 
is necessary to use control for each investigated time point after aCD20 treatment to 
investigate the repletion kinetic. For each investigated point in time, the B cell frequency of 
control treated mice was set at 100% and B cell frequency of aCD20 treated mice was 
normalized to this value. 
In week 7, the reappearance of B cells was observed in the spleen and in the bone marrow. 
In contrast, in the blood and the lymph node no B cells were detectable at this time. Around 
week 9, upon the last aCD20 treatment, B cells reappeared in the blood and the lymph node. 
In week 12, B cells were fully repleted in all investigated compartments (figure 7). 
The repletion kinetic of B cells after aCD20 treatment in rMOG EAE started in the spleen and 
the lymph node. B cells reappeared earlier in rMOG EAE compared to repletion MOG p35-55 
and naïve mice around week 6. A further difference between the repletion kinetics was seen 
in rMOG immunized mice: the repletion started in the lymph nodes and the blood 
simultaneously. B cell reappearance was more distributed in all investigated compartments 
in comparison to mice with MOG p35-55 EAE. The B cell repletion in mice with rMOG EAE 
was fully completed after the last treatment. 




Figure 7: Repletion kinetic in EAE models. 
Repletion kinetic of B cells in spleen, bone marrow, lymph node and blood after preventive 
aCD20 Ab treatment or control Ab in MOG p35-55 EAE (a) or rMOG EAE (b) after aCD20 
treatment normalized to a time according control. Mean of two different experiments is 
shown with n=2 per group and point in time for each experiment was normalized to time 
according control. 
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3.1.4. Clinical score after aCD20 treatment in the EAE model 
 
Figure 8: Reappearance of B cells causes different clinical outcome in rMOG and MOG p35-55 
EAE. 
C57Bl6/j mice were treated three times with aCD20 or control Ab and then immunized with 
rMOG or MOG peptide. The disease score was monitored daily (s. material and methods). 
Mean score of n= 4-7 mice per group is shown. 
 
To address the question what the clinical effect of aCD20 treatment in mouse EAE is, the 
clinical score of the two models was evaluated. The MOG p35-55 EAE is a T cell induced EAE 
model where B cells are not activated. In contrast, rMOG EAE is a T cell and B cell mediated 
model in which B cells are actively involved. 
In MOG p35-55 induced EAE, a clinical worsening can be observed after preventive treatment 
with aCD20 antibody (figure 8 b). The most significant difference between control group and 
aCD20 treated group was found at day 18, defined as the peak of the disease (p<0.05) or the 
inflammatory phase after immunization. This clinical worsening stagnates after the 
reappearance of B cells (day 60, p>0.05).  
In contrast, in rMOG EAE (figure 8 a) where B cells are actively involved in EAE progression, 
the development of the clinical effect was the other way around; B cell depletion (aCD20 
treated group mean score 1.5±0.42) caused a significant clinical benefit compared to the 
control treated group (mean score 3.35±0.26, p>0.05) at the peak of the disease. However, 
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this effect was abolished after reappearance of B cells. When B cells were fully repleted no 
the clinical difference between the groups were detected (day 60, p>0.05). 
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3.1.5. Characterization of reappearing B cells in EAE 
3.1.5.1. Phenotyping of reappearing B cells in EAE 
 
The previous experiments in this study revealed that remaining B cell population of CD27+ 
activated B cells is enriched after aCD20 treatment. Furthermore, we measured differences 
in the repletion kinetic between our two EAE models. This leads to the hypothesis that the 
reappearing B cells are more activated in mice with rMOG EAE than in the T cell mediated 
EAE model, induced by MOG p35-55. 
In the following experiments the phenotype of reappearing B cells were characterized by 
FACS analysis after aCD20 or control treatment by using several markers.  
By analysing CD23 expression, a marker for mature B cells, in reappearing B cells in rMOG 
EAE (1.22±0.15%) the expression was significantly reduced compared to CD23+ B cells 
(68.6±1.75%). The same tendency was found in MOG p35-55 EAE. Here, the CD23 expression 
of the reappearing B cells (22.4±6.2%) was higher in comparison to rMOG EAE. The CD23 
expression of both controls, rMOG (66.8±1.75) and MOG p35-55 EAE (68.8±0.55), were at a 
comparable level (figure 9). 
The upregulation of CD27 in the reappearing B cells was most substantial finding. The highest 
CD27 expression was measured in reappearing B cells of mice with rMOG EAE with 
73.45±2.65% compared to the control with 19.35±0.07% CD27 expressing B cells. In MOG 
p35-55, CD27 expression was upregulated in reappearing B cells (43.00±2.65%) compared to 
the B cells of control treated mice (18.87±3.72%). 
Additionally, the analysed frequency of plasma blasts (CD138+ MHII-) and plasma cells 
(CD138+ MCHII+) showed a gentle increase in reappearing B cells of mice with rMOG EAE 
(plasma blast: reappearing B cell 13.29±2.31 vs. 10.63±2.06% ctrl treated B cells; plasma cell: 
reappearing B cell 19.9±1.25% vs 5.45±0.25% ctrl treated B cells) but a reduction in mice with 
MOG p35-55 EAE (plasma blast: reappearing B cell 9.28±0.42 vs 14.88±0.98% ctrl treated B 
cells; plasma cell: reappearing B cells 11.79±0.67% vs 5.33±0.83% ctrl treated B cells). This 
could be due to the frequency shift caused by the missing depleted B cell population. Thus, 
the population of plasma blast and plasma cells might not be affected by the aCD20 
treatment. 
In addition, the phenotype of reappearing B cells in week 12 was analysed after the last 
aCD20 treatment when B cells are fully repleted in all immune relevant compartments. 
Reappearing B cells of mice with rMOG EAE consist of more CD27+ activated B cells than the 
corresponding control. However, the CD23 expression is still lower in repleted B cells than in 
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control treated mice, but higher compared to CD23 expression in reappearing B cells in week 
8. 
In contrast, the reappearing of B cells of mice with MOG p35-55 EAE model showed no 
difference in the composition of B cells compared to their respective controls. Only the 
frequency of CD27+ expressing B cells is still higher (~2.5%) while frequencies of CD23+ B 
cells, plasma blast and plasma cells are at a comparable level. 
In summary, B cells which reappeared in mice of the rMOG EAE model showed a more 
activated phenotype than B cells in control treated mice. Additionally, B cells which 
reappeared in mice of the MOG p35-55 EAE-model also showed a more differentiated 
phenotype their control but less than reappearing B cells of mice in the rMOG EAE model. 
The difference between these two different EAE models is even pronounced after the full 













Figure 9: Phenotyping of reappearing B cells 8 and 12 weeks after last aCD20 Ab treatment. 
a) Representative FACS plots show the frequencies of CD23+ B cells, CD27+ Memory B cells, 
plasma blast and plasma cells of all CD19+ B cells. b) shows the B cells subtypes in percentage of 
CD19+ B cells. c) shows the percentage of CD23+ B cells, CD27+ B cells, plasma blast and plasma 
cells. The sum of this whole B cell pool was set to 100%. Representative experiment of n=2 per 
group and time point is shown. 
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3.1.5.2. Cytokine release after LPS or CpG stimulation 
 
Figure 10: Cytokine release of reappearing B cells after LPS or CpG stimulation. 
a) IL-10 and b) IL-6 release of isolated reappearing B cells (week 8 or 12 after last treatment) 
of aCD20 Ab treated or control treated B cells were stimulated with different concentrations 
of LPS or CpG. Cytokines were measured in the supernatant by ELISA. Mean of n=3 per group 
and time point is shown. 
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To identify the difference of reappearing B cells in rMOG EAE as well as in MOG p35-55 EAE, 
the release of IL-6, a pro-inflammatory cytokine, and IL-10, an anti-inflammatory cytokine, 
were investigated after LPS and CpG stimulation. Here the immune response of the two 
different B cell phenotypes was characterized. 
The results show that the IL-10 release was significantly decreased in reappearing B cells of 
mice with rMOG EAE (5µg/ml LPS: reappearing B cells 0pg/ml vs 132.7±8.59pg/ml ctrl treated 
B cell, p>0.0001; 10µg/ml LPS: reappearing B cells 0.7±0.66pg/ml vs 143.1±21.9pg/ml ctrl 
treated B cell, p>0.005; 1µg/ml not detectable; 10µg/ml: reappearing B cells 0pg/ml vs 
233.1±12.58pg/ml ctrl treated B cell p>0.001) and mice with MOG p35-55 EAE (5µg/ml LPS, 
p>0.0001; 10µg/ml LPS, p>0.0005; 1µg/ml CpG not detectable; 10µg/ml CpG, p>0.0001) after 
LPS as well as after CpG stimulation (1µg/ml not detectable; 10µg/ml p>0.0001) in week 8 
after the last treatment with aCD20 Ab (figure 10 a). In week 12 after the last treatment, the 
IL-10 release was higher in reappearing B cells compared to their control (5µg/ml LPS 
p<0.005; 10µg/ml LPS p>0.0005; 1µg/ml CpG p>0.005; 10µg/ml CpG p>0.005), while repleted 
B cells of mice with MOG p35-55 EAE released a lower amount of IL-10 in comparison to B 
cells of control treated mice after LPS and CpG (5µg/ml LPS p<0.005; 10µg/ml LPS p>0.005; 
1µg/ml CpG p>0.005; 10µg/ml CpG p>0.005).  
The release of the cytokine IL-6 was significantly lower in reappearing B cells in comparison 
to B cells of control treated mice in the rMOG EAE in week 8 after aCD20 treatment (5µg/ml 
LPS p>0.01; 10µg/ml LPS p>0.001; 1µg/ml CpG p>0.001; 10µg/ml CpG p>0.001) (figure 10 b). 
At week 12 after last aCD20 treatment B cells are fully repleted and the released amount of 
IL-6 was significant higher after stimulation with 5µg/ml LPS (p<0.05). After 10µg/ml LPS 
stimulation, the released IL-6 showed no significant difference compared to the B cells of 
control treated mice. Also, no significant difference in the release of IL-6 was observed after 
CpG stimulation. In MOG p35-55 EAE, no significant difference was found in the released 
amount of IL-6 compared to reappearing B cells and B cells of control treated mice (p>0.05). 
In contrast, reappearing B cells of mice in MOG p35-55 EAE showed a lower amount of 
released IL-6 after CpG stimulation even after full repletion of the B cells (1µg/ml CpG p<0.01; 
10µg/ml CpG p<0.01). 
 
3.1.5.3 Higher rMOG binding ability of reappearing B cells in rMOG EAE 
For analysing antigen-binding capacity, isolated reappearing B cells were incubated with 
fluorescence labelled rMOG protein.  
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Reappeared B cells, 8 weeks after the last aCD20 treatment, showed a 5.36±0.22 % binding 
of rMOG (figure 11), which was significantly higher than in the control group (4.59± 0.21%, 
p<0.05). In contrast, reappearing B cells in MOG p35-55 EAE (3.50±0.05%) displayed a similar 
binding ability compared to the control treated B cells (3.59±0.11%, p>0.05). Further 
observation revealed a generally lower, however not significant, rMOG binding of isolated B 
cells od MOG p35-55 EAE in comparison to the B cells of the rMOG EAE (figure 11). 
Thus, reappearing B cells of mice with rMOG EAE is able to bind more rMOG protein, while B 
cells in MOG p35-55 EAE mice showed no difference in rMOG binding ability. 
 
Figure 11: Increased rMOG binding to reappearing B cells in rMOG EAE. 
B cells of aCD20 or control treated mice of a) rMOG EAE or b) MOG p35-55 EAE was incubated 
with fluorescence labelled rMOG for 2h. Shown is one representative experiment of 4 n=3 per 
group. 
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3.1.6. Functional characterization of reappearing B cells in two EAE models 
 
3.1.6.1. Superior antigen presenting function of reappearing B cells in rMOG EAE 
In the previous part, it was established that reappearing B cells in the rMOG EAE model showed 
a phenotype with signs of higher activation. Particularly, reappearing B cells showed differences 
in the cytokine release after LPS or CpG stimulation compared to B cells from control treated 
mice.  
To analyse this phenomenon, further characterization of functional differences was needed and 
therefore reappearing B cells or B cells from control treated mice were isolated from mice in 
rMOG EAE or MOG p35-55 EAE model and incubated with MOG specific T cells from 2D2 mice. 
This co-culture of T and B cells was re-stimulated according to their immunization stimulus with 
rMOG protein or MOG p35-55. To measure T cell proliferation, the MOG specific T cells were 
stained with CFSE to investigate the different proliferation stages. After every cell division the 
fluorescent intensity is halved due to the divided amount of CFSE is between each cell (figure 12 
a). 
Reappearing B cells of mice with rMOG EAE induced a significantly higher T cell proliferation of 
MOG specific T cells (figure 12 b) in comparison to B cells of control treated mice. In contrast, 
reappearing B cells compared with B cells of control treated mice of MOG p35-55 EAE showed a 
lower T cell proliferation rate. In figure 12 c) the T cell proliferation, caused by reappearing B 
cells, was normalized to the T cell proliferation rate caused by the control treated B cell control 
after the last aCD20 treatment at different points in times. At every investigated point in time, 
the reappearing B cells induced a higher T cell proliferation in MOG specific T cells compared to 
the control treated B cells (grey points: week 7 mean 132.1±21.39%, week 8 mean 
130.08±3.15%, week 12 mean 135.67±25,48%, week 14 mean 134.23±11.85%, week 
18=144.30%). The T cell proliferation rate induced by the reappearing B cells from MOG p35-55 
EAE mice was normalized to their control. Here, the T cell proliferation, caused by reappearing 
B cells, is lower or similar compared to the proliferation rate caused by the B cells of control 
treated mice (black points: week 7 mean 75.69±15.17%, week 8 mean 90.16±2.5%, week 12 
mean 87.28±4.52%, week 14 mean 80.30±4.96%, week 18=77.37%).  
In summary, reappearing B cells of rMOG EAE mice are superior antigen presenting cells 
compared to B cells of control treated mice after re-stimulation with the antigen used for 
immunization and to reappearing B cells of MOG p35-55 EAE mice. 




Figure 12:  Increased T cell proliferation caused by reappearing B cells in rMOG EAE. 
a) shows a schematic representation of the experimental setting. b) shows representative FACS 
plots of T cell proliferation caused by reappearing B cells or control-treated B cells of mice 
immunized with rMOG or MOG peptide. c) shows the T cell proliferation rate normalized to the 
respective control treated group at the identical points in time after the last aCD20 treatment. 
Single dots show mean of one experiment with n=2 per group and time point. 
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3.1.6.2. Cytokine release during antigen presentation  
To understand how B cells influence T cells during antigen presentation, cytokine release was 
measured in the supernatants by ELISA. The supernatants were analysed for cytokines 
commonly released by T cells.  
In week 8 after aCD20 treatment (figure 13 a), the co-cultured T cells and reappearing B cells 
(583.9±24.6pg/ml IFN ƴ) released more IFN ƴ compared to the co-culture with B cells of control 
treated mice (7.49±4,75pg/ml IFN ƴ). IL-17 was not detected in the co-culture in any condition. 
Furthermore, the IL-6 release of co-cultured reappearing B cells of rMOG EAE mice 
(97.37±31.44pg/ml IL-6) was increased compared to co-cultured B cells of control treated mice 
of rMOG EAE (6.06±3.64pg/ml IL-6). The co-culture of reappearing B cells of MOG p35-55 EAE 
(41.88±8.43pg/ml IFN ƴ) mice showed a significantly lower amount of released IFN ƴ compared 
to the co-culture with B cells of control treated mice (70.04±5.12pg/ml IFN ƴ). In general, a 
significantly lower release of IFN ƴ was measured in reappearing B cells of MOG p35-55 EAE than 
in the co-culture with B cells from the rMOG EAE mice. The IL-6 release in B cells of MOG p35-
55 EAE mice was also lower compared to the co-culture with B cells from the rMOG EAE mice. 
However, the co-cultured reappearing B cells of MOG p35-55 EAE mice (51.83±16.38pg/ml IL-6) 
showed a higher release of IL-6 compared to the co-culture of control B cells (27.31±3.03pg/ml 
IL-6). 
At week 12 after the last aCD20 treatment (figure 13 b), B cells were fully repleted and the co-
culture of reappearing B cells in rMOG EAE caused a higher MOG specific T cell proliferation 
(24.58±7.52% CD4+ proliferation) compared to T cell proliferation rate caused by B cells of 
control treated mice (18.05±2.75% CD4 proliferation). Simultaneously IL-2 release of co-culture 
of reappearing B cell (536.9±32.67pg/ml IL-2) and B cells of control treated mice 
(590.6±174.6pg/ml IL-2) was similar. The released IFN ƴ level of reappearing B cell co-culture 
(424.7±120.3pg/ml IFN ƴ) showed a higher amount of released IFN ƴ compared to co-culture of 
B cells of control treated mice (248.7±115.4pg/ml IFN ƴ). Furthermore, 8 weeks after the last 
aCD20 treatment, the release of IL-17 and IL-6 was also increased compared to the cytokine-
release–profile of rMOG EAE mice.  
The results of reappearing B cells of MOG p35-55 EAE mice 12 weeks after the last treatment 
were similar to the results gained 8 weeks after the last aCD20 treatment. Proliferation of 
reappearing B cells (61.3±1.25% CD4+proliferation) was higher in B cells 12 weeks after the last 
treatment compared to the B cells of control treated mice (40.55±11.45% CD4+ proliferation) in 
MOG p35-55 EAE mice but not significantly altered in rMOG EAE mice. The measured IL-2 
production was similar in co-culture of reappearing B cells (536.9±32.67pg/ml) compared to B 
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cells of control treated mice (590.4±174.6pg/ml) in rMOG EAE. IFN ƴ, IL-17 and IL-6 release was 
still higher in reappearing B cells in rMOG EAE compared to co-culture of B cells of control 
treated mice. In contrast, proliferation rate and IL-2, IFN ƴ, as well as IL-17 release of reappearing 
B cells was lower compared to the co-culture of control treated mice in MOG p35-55 EAE mice 
IL-6 released by reappearing B cells was comparable to B cells of control treated mice.  
To summarize, reappearing B cells of rMOG EAE in co-culture with T cells produced more pro-
inflammatory T cell cytokines compared to the B cells of control treated mice, while the cytokine 
profile in MOG p35-55 EAE showed a less inflammatory cytokine profile. 




Figure 13: Cytokine release and proliferation rate of co-cultured MOG specific T cells and 
reappearing B cells in rMOG and MOG p35-55 EAE. 
The release of IL-17, IFN ƴ, IL-6 and IL-2 from the co-culture of MOG specific T cells and 
reappearing B cells or control treated B cells of rMOG or MOG p35-55 EAE at week 8 (a) or 
week12 (b) after last treatment is shown. Means of one representative experiment are shown 
n=2 per group and point in time. 
 




3.1.7. In vivo proliferation of B cells after aCD20 treatment 
 
3.1.7.1 Increased in vivo proliferation after aCD20 depletion in the EAE model 
 
Figure 14: Increased in vivo proliferation of remaining B cells 8 weeks after aCD20 Ab 
treatment. 
a) B cell and b) T cell proliferation after aCD20 or control treatment was investigated after BrdU 
injection and afterwards stained intracellular for BrdU+ cells and analysed by FACS. 
Representative FACS plots are shown and bar graphs show mean of one representative 
experiment out of three (n=3 per group).  
 
 
To research the effect of aCD20 treatment on B cells in vivo, mice were immunized with rMOG 
or MOG p35-55 after aCD20 or control treatment followed by a BrdU-injection ten days after 
immunization, which allows the investigation of cell-proliferation after injections. Two days after 
BrdU-injection, spleen and lymph nodes were investigated for cell proliferation. 
In the spleen, remaining B cells in rMOG, as well as in MOG p35-55 EAE showed a significantly 
higher proliferation rate than their controls (figure 14). B cells of control treated mice in rMOG 
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EAE exhibited a proliferation rate of 3.56±0.98%, which was significantly lower compared to the 
remaining B cells (27.6±2.26%, p<0.001). Indeed, the remaining B cells in MOG p35-55 EAE mice 
showed a proliferation rate of 13.14±6.5%, while the B cells of control treated mice had lower 
proliferation rate (3.6±0.43%, p>0.05). In the lymph node, the remaining B cells showed a higher 
proliferation compared to the B cells of control treated mice in rMOG (reappearing B cells 
18.48±5.49% vs. ctrl treated B cells 4.05±1.50%, p>0.05) as well as B cells of mice in MOG p35-
55 (remaining B cells 30.12±6.84% vs. ctrl treated B cells 2.09±0.26%, p<0.05). 
Analysation of the T cell proliferation revealed no significantly altered proliferation rates of 
aCD20 and control treated animals in rMOG EAE in spleen (aCD20 treated 5.01±0.41% vs. ctrl 
treated 4.06±0.27%, p>0.05). In contrast, T cells of MOG p35-55 EAE mice treated with aCD20 
Ab showed a significantly higher proliferation rate compared to control treated mice (aCD20 
treated 7.75±1.19% vs. ctrl treated 2.7±0.78%, p<0.05).In the lymph node, T cells of aCD20 Ab 
treated mice exhibited a significantly higher proliferation rate compared to control treated mice, 
as well as T cells of mice with rMOG EAE (aCD20 treated 1.18±0.54% vs. ctrl treated 1.53±0.29%, 
p>0.05) and T cells of mice with MOG peptide EAE (aCD20 treated 1.91±0.35% vs. ctrl treated 
1.19±0.19%, p>0.05). 
This experiment showed that remaining B cells had a higher proliferation rate independent of 
immunization. Moreover, the findings suggest that B cell depletion also influenced the T cell 
proliferation, leading to a higher T cell proliferation rate. 
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3.1.7.2. In vivo proliferation of B and T cells 8 weeks after aCD20 Ab treatment 
 
Figure 15: Increased in vivo proliferation of reappearing B cells 8 weeks after aCD20 Ab 
treatment. 
a) B cell and b) T cell proliferation in the spleen, 8 weeks after aCD20 Ab or control Ab treatment, 
was investigated after BrdU injection and followed by intracellular staining for BrdU+ cells and 
analysis via FACS. Representative FACS plots are shown and the bar graphs represent the mean 
of n=4 per group.  
 
In the previous experiments, the remaining B cells in the spleen as well as in lymph nodes 
showed a higher proliferation rate after aCD20 Ab treatment compared to their control. To 
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address the question whether these highly proliferating remaining B cells are the ones which 
reappear after 8 weeks, the same experiment was performed again 8 weeks after the last 
treatment and BrdU was injected at the end of week 7 to investigate the proliferation rate. 
When B cells started to reappear around week 7, the B cell proliferation in the spleen was 
significantly increased compared to the control treated mice with rMOG EAE (reappearing B cells 
65.01% vs 11.15% ctrl treated B cells BrdU+, p<0.01) as well as in MOG p35-55 EAE mice 
(reappearing B cells 62.01% vs 15.08% ctrl treated B cells BrdU+, p<0.01) (figure 15). In the lymph 
node, the B cell proliferation rate of reappearing B cells was increased, but not significant in both 
EAE rMOG (reappearing B cells 8.80% vs 17.13% ctrl treated B cells BrdU+, p>0.05) and MOG 
p35-55 (reappearing B cells 29.28% vs 16.18% ctrl treated B cells BrdU+, p>0.05). However, the 
proliferation rate of B cells in the bone marrow was low (3.48-10.48% proliferation) and not 
significantly increased in the reappearing B cells (p>0.05). 
To investigate the effect of B cell depletion on T cells, the T cell proliferation was measured at 
the time of B cell reappearance. In spleen, the T cells of the restored mice did not show an 
increased proliferation rate in rMOG EAE mice (reappearing B cells 11.56% vs 12.13% ctrl treated 
B cells BrdU+, p>0.05) or MOG p35-55 (reappearing B cells 17.75% vs 14.85% ctrl treated B cells 
BrdU+, p>0.05).The same trend was seen in lymph nodes. However, the T cell proliferation in 
the bone marrow was significantly reduced in aCD20 treated mice compared to control treated 
mice (rMOG: reappearing B cells 10.09% vs 8.35% ctrl treated B cells BrdU+, p<0.05;MOG p35-
55: reappearing B cells 13.41% vs. 8.89% ctrl treated B cells BrdU+, p<0.05). 
In summary, the remaining B cells started to proliferate in the spleen, where repletion of B cells 
started. Furthermore, the performed experiments showed that the reappearance of B cells did 
not influence T cell proliferation in both EAE models. 
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3.2. Direct and indirect effects on T cells after aCD20 treatment 
 
3.2.1. Dynamics of the T cell population during B cell repletion 
We investigated the T cell population in C57Bl6/j mice after a threefold aCD20 or control 
treatment. To analyse the influence of aCD20 treatment on the T cell population, we 
investigated the CD3+ T cell frequency during B cell repletion. 
The first finding was a relative increase in the frequency of T cells in all investigated 
compartments due to the missing B cell population. The CD3+ T cell frequency was 
normalized to the time according control in figure 16. Until the B cells started to reappear at 
week 8 after the last aCD20 treatment, the T cell frequency was at least 180% of the 
frequency in control treated mice and nearly returned to normal in all investigated 
compartments at week 12, when B cells were fully repleted. 
This shift of the CD3+ T cell frequency was caused by the missing B cell population and 
rebalanced after the reappearance of B cells. 




Figure 16: CD3+ T cell frequency during B cell repletion after aCD20 treatment. 
a) CD3+ T cell frequency in spleen, lymph node, bone marrow and blood after aCD20 
treatment was normalized to control. b) shows representative FACS plots of all investigated 
compartments for the analysed time points. Repletion kinetic shows mean of n=2 per group 
and time point. 
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3.2.2. Characterization of the T cell population after aCD20 treatment 
The missing B cell population led to an increased frequency of CD3+ T cells in all investigated 
compartments (figure 17). Following the relative extension of B cell depletion, the highest 
increase was observed in the spleen, blood and lymph nodes, while the bone marrow showed 
the smallest frequency shift. In contrast, the absolute numbers of T cells, as well as in CD4+ and 
CD8+ T cells, was decreased in the spleen. A significant increase of CD8+ T cells in contrast to 
the control treated group could only be observed in the bone marrow. 
 
Figure 17: Increased T cell frequency and decreased absolute number of T cells after aCD20 
treatment. 
a) shows CD3+ T cell frequency after a threefold treatment with aCD20 Ab or control Ab 
treatment. b) exhibits the absolute number of the T cell frequency divided into CD4+ and CD8+ T 
cells. The mean of n= 3 per group is displayed. 
 
We investigate whether the decreased number of T cells is due to a direct effect of aCD20 Ab 
depletion or an indirect effect of missing B cell interaction with T cells. T cells were stained 
for CD20 expression. 
We found a CD4+CD20+ T cell population in the spleen, which was significantly reduced after 
a threefold aCD20 treatment compared to the control (aCD20 treated group 2.84±0.60% vs. 
7.34±1.11% ctrl treated group, p<0.05). In the lymph node (aCD20 treated group 3.2±0.57% 
vs. 7.45±1.41% ctrl treated group, p<0.05) and blood (aCD20 treated group 0.54±0.13%vs 
12.4±1.35% ctrl treated group, p<0.05), the CD4+CD20+T cell population was significantly 
reduced compared to the control treated group (figure 18). The CD4+CD20+ T cell frequency 
was significantly reduced in the bone marrow after aCD20 treatment from 13.28±1.49% in 
control treated mice to 6.54±0.69% after aCD20 treatment (p<0.05). 
  3. Results 
58 
 
In addition, we found a CD8+CD20+ T cell population in all investigated compartments. In the 
control group, the CD8+CD20+ T cell population was 11.44±2.57% and thus significantly 
higher than 2.93±0.60% in the aCD20 treated group in the spleen (p<0.05). The strongest 
reduction was observed in the blood. Here, nearly no CD8+CD20+ T cells could be measured 
after CD20 treatment (aCD20 treated group 0.38±0.02%vs. 5.58±1.97% ctrl treated group, 
p<0.05). A significant reduction was observed in the lymph node (aCD20 treated group 
2.28±0.32% vs. 1.12±0.14% ctrl treated group, p<0.05), but not in the bone marrow (aCD20 
treated group 0.91± 0.10% vs. 4.69±2.15% ctrl treated group, p>0.05). 




Figure 18: Characterization of T cells after CD20 treatment. 
Representative FACS plots show (a) the CD4+CD20+ T cells and (b) the CD8+CD20+ T cell 
frequency and the according mean of the spleen, lymph node, bone marrow and blood. The mean 
of n=3 per group is displayed. 
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3.2.3. CD20+ T cell repletion 
To assess whether the depleted CD20+ T cell population is able to reappear after treatment 
termination, observations at different points in time were analysed. 
The CD20+ T cell population was depleted after three times of the aCD20 treatment in all 
investigated compartments, shown in figure 19. Similar to the B cell repletion kinetic after 
week 4 to 7, no CD20+ T cells reappeared in any investigated compartment. At week 8 after 
the last aCD20 treatment the CD3+CD20+ T cell population reappeared in all investigated 
compartments. In contrast, in naïve mice, B cells reappeared only in the spleen and lymph 
node. The CD3+CD20+ T cell repletion was completed in all investigated compartments at 
week 12 after the last aCD20 treatment. 




Figure 19: Repletion kinetic of CD20+CD3+ T cells after aCD20 treatment. 
a) the frequencies of CD20+ CD3+ T cells are shown after three times of aCD20 treatment. T 
cell frequencies of spleen, lymph node, bone marrow and blood are normalized to control for 
each observation time. b) shows frequencies of CD20+CD3+ T cells after three times of aCD20 
or control treatment and 12 weeks after the last aCD20 treatment. c) Representative FACS 
plots of CD20+CD3+ frequencies of all investigated compartments are shown during B cell 
repletion. Mean of n=2 per group and point in time. 
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3.2.4. CD20+ T cell repletion in EAE 
The analysis of the CD20+ T cell population after aCD20 treatment in MOG p35-55 EAE showed 
a repletion kinetic of CD20+ T cells comparable to that in naïve mice after aCD20 treatment 
(figure 19). The repletion of CD20+ T cells started in the spleen, lymph node and bone marrow 
at week 8 after the last aCD20 treatment. In the blood, CD20+ T cells were detected for the first 
time at week 10 after the last treatment. A full repletion of CD20+ T cells was measured at week 
12, while the spleen, lymph node and blood showed an exceeding CD20+ T cell frequency at this 
time (spleen 203.88%, lymph node 187.8%, blood 119.42%, bone marrow 93.55%). 
Comparing the repletion kinetic of CD20+ T cells in MOG p35-55 and rMOG EAE mice (figure 20), 
the reappearance of the CD20+ T cells started slightly earlier in mice with rMOG EAE (week 7 
spleen: 94.72% CD20+T cells of control treated) than in MOG p35-55 (week 7 spleen: 42.42% 
CD20+T cells of control treated). CD20+ T cells in the blood of rMOG EAE mice remain on the 
same level from week 4 (week 4: 55.00% CD20+T cells of control treated) up to week 12 (week 
12: 60.23% CD20+T cells of control treated). The exceeding CD20+ T cell frequency was also 
measured in the bone marrow of rMOG EAE mice at week 8 (190.68% CD20+T cells of ctrl 
treated) and in their spleen at week 10 (176.36%CD20+T cells of ctrl treated) after last aCD20 
treatment. 
The CD20+ T cell repletion started in mice with rMOG EAE slightly earlier than in mice with MOG 
p35-55 EAE. Furthermore, both repletion kinetics showed an excess of CD20+ T cells in the 
spleen, occurring at different points of time. Here, the excess of CD20+ T cells was measured 
earlier in rMOG EAE than in MOG p35-55 EAE. 
 




Figure 20: CD20+ T cell repletion in different EAE-models. 
The frequency of CD20+ CD3+ T cells after aCD20 treatment was normalized to the time 
according to control for different observation times in the spleen, lymph node, bone marrow 
and blood in a) MOG p35-55 and b) rMOG EAE mice. The mean of n=2 per group and time point 
was normalized to time according to control. 
 
3.2.5. Direct stimulation of T cells of naïve mice after aCD20 treatment ex vivo 
The previous experiments showed that aCD20 treatment has a direct effect on the T cell 
population by depletion of CD20+ T cells. To address the question whether the missing 
interaction with the depleted B cells has an influence on the functional behaviour of T cells, 
isolated CFSE stained T cells were stimulated with aCD3/aCD28 antibodies and their 
proliferation was measured. 
8 weeks after aCD20 treatment (figure 21 a), T cells showed a significantly lower proliferation 
rate after stimulation with aCD3/aCD28 Ab compared to the T cells of the control-treated 
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group (aCD20 treated group 45.58±1.02% vs. 56.05±% ctrl treated group, p<0.01). Similarly, 
a not significant (p>0.05) tendency in T cell proliferation could also be observed 12 weeks 
after aCD20 Ab treatment, where B cells were completely repleted. 
Furthermore, IL-17 release was significantly inhibited after aCD20 treatment in T cells after 8 
weeks (aCD20 treated group 38.19±8.23pg/ml vs. 76.64±9.92pg/ml ctrl treated group, 
p<0.05). After 12 weeks (figure 21 b), the difference in IL-17 release between aCD20 treated 
T cells and control treated T cells were no longer significant (aCD20 treated group 
300.6±28.41pg/ml vs. 382.2±79.88% ctrl treated group, p>0.05). Meanwhile, the release of 
IFN ƴ and IL-6 was not significantly affected by aCD20 treatment (p>0.05). GM-CSF release 
did not differ between aCD20 treatment and T cells of control treated mice 8 weeks after the 
last treatment (p>0.05). In contrast, GM-CSF release was significantly reduced after 
aCD3/aCD28 stimulation (aCD20 treated group 4042.0±109.5pg/ml vs 4517.0±2.6%ctrl 
treated group, p<0.01), but not under unstimulated conditions (p>0.05). 




Figure 21: Reduced proliferation and cytokine release of aCD20 treated T cells after 
aCD3/aCD28 stimulation in naïve mice after aCd20 treatment. 
The proliferation rate of CD3+T cells after aCD3/aCD28 Ab stimulation (0µg/ml aCD3 and 
10µg/ml aCD28; 0.25µg/ml aCD3 and 10µg/ml aCD28) is reduced in the absence of B cell. The 
cytokine release of IFN ƴ, IL-17, GM-CSF and IL-6 were measured in the supernatant by ELISA. 
The mean is shown of n=3 per group and point in time. 
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3.2.6. Direct ex vivo stimulation of T cells in EAE after aCD20 treatment  
 
Figure 22: Reduced proliferation and cytokine release of aCD20 treated T cells after 
aCD3/aCD28 stimulation in rMOG and MOG p35-55 EAE after aCD20 treatment. 
The proliferation rate of CD3+T cells after aCD3/aCD28 Ab stimulation (unstimulated 
condition: 0µg/ml aCD3 and stimulated condition 10µg/ml aCD28; 0.25µg/ml aCD3 and 
10µg/ml aCD28) in rMOG and MOG p35-55 EAE is shown. The cytokine release of IFN ƴ and 
IL-17 were measured in the supernatant by ELISA. The mean of n=3 per group and time point 
is displayed. 
 
To answer the question what impact aCD20 treatment would have on the T cell side of EAE, T 
cells of rMOG EAE and MOG p35-55 EAE mice were isolated and directly stimulated with 
aCD3/aCD28 antibodies. Afterwards, the proliferation and cytokine release were measured. 
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CD3+ cell proliferation was not significantly lower after aCD3/aCD28 stimulation, which was 
performed 8 weeks after aCD20 treatment in rMOG EAE mice (aCD20 treated group 
2.65±0.48pg/ml vs. 19.31±7.92pg/ml ctrl treated group, p>0.05). Following aCD3/aCD28 
stimulation of T cells of mice with MOG p35-55 EAE (figure 22), the T cell proliferation was not 
significantly reduced in T cells isolated from mice, treated with aCD20 Ab, compared to T cell 
proliferation of control treated mice (aCD20 treated group 4.90±0.8%vs. 76.52±5.42% ctrl 
treated group, p<0.01). 12 weeks after aCD20 treatment, B cells fully reappeared and the 
tendency of a lower proliferation rate after aCD20 treatment was no longer measurable. In MOG 
p35-55, the proliferation of aCD20 treated T cells was still significantly lower following 
aCD3/aCD28 stimulation compared to the T cells of control treated mice (p<0.05). 
T cells of aCD20 treated mice 8 weeks after the last treatment showed a significantly reduced 
IFN ƴ release in rMOG EAE (aCD20 treated group 0±0pg/ml vs. 1252±380.5pg/ml ctrl treated 
group, p<0.05) and MOG p35-55 EAE (aCD20 treated group 14.25±11.45pg/ml vs. 
3606±147.9pg/ml ctrl treated group, p<0.01) compared to their controls. Fitting to the 
proliferation rate, 12 weeks after the last aCD20 treatment, the release of IFN ƴ was not 
significantly reduced in aCD20 treated T cells compared to T cells of control treated mice in 
rMOG EAE (aCD20 treated group 5640±513pg/ml vs. 5103±1209pg/ml ctrl treated group, 
p>0.05). However, IFN ƴ was still significantly reduced in aCD20 treated T cells in MOG p35-55 
EAE compared to their control treated mice (aCD20 treated group 3363±1051pg/ml vs. 
8295±191.4pg/ml ctrl treated group, p<0.01). The same release profile was observed for the IL-
17 release. IL-17 release was significantly reduced in T cells after aCD20 treatment from 
330.±14.2pg/ml to 269.8±18.82pg/ml in rMOG EAE mice after aCD3/aCD28 stimulation (p<0.05). 
In MOG p35-55 EAE mice, the IL-17 release of T cells was significantly reduced after aCD20 
treatment from 398.6±46.04pg/ml to 185.6±21.98pg/ml (p<0.01). 
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3.3. CNS infiltration of B cells, T cells and myeloid cells in the dynamics of B cell 
repletion in EAE 
In previous experiments of this study, reappearing B cells of rMOG EAE mice showed a more 
activated phenotype and ex vivo a superior APC function than their control. To investigate if 
these more activated reappearing B cells also exhibit a higher infiltration of immune cells in 
the CNS compared to control treated mice in rMOG and MOG p35-55 EAE, the histology of 
CNS 14 weeks after the last aCD20 treatment was analysed. 
In the CNS of aCD20 treated rMOG EAE mice (figure 23), the B cell number was decreased 
(0.88±0.46 B cells/mm2 white matter) compared to the control treated mice (5.85±2.04 B 
cells/mm2 white matter, p>0.05). The same trend was observed for the B cell infiltration in 
the white matter of MOG p35-55 EAE. Here, the B cell number in the CNS of aCD20 Ab treated 
mice (0.69±0.31 B cells/mm2 white matter) was lower compared to the control treated mice 
(4.21±1.73 B cells/mm2 white matter, p>0.05).  
The T cell side is also affected by the repletion of B cells. T cell infiltration was investigated in 
the CNS after B cell repletion. Similar to the B cell infiltration in the white matter, the amount 
of T cells was significantly decreased in aCD20 treated mice compared to the control treated 
mice in rMOG EAE (aCD20 treated 6.87±1.57 T cells/mm2 white matter; ctrl treated 
14.32±2.59 T cells/mm2 white matter, p<0.05). In contrast, no significant difference was 
observed in mice of MOG p35-55 EAE (aCD20 treated 8.14±2.08 T cells/ mm2 white matter, 
ctrl treated Ab 22.73±8.88 T cells/ mm2 white matter, p>0.05). 
A different observation could be made for MAC-3+ cells, which were significantly increased 
in the CNS of aCD20 treated mice in MOG p35-55 (p<0.05). The same trend could be observed 
in rMOG EAE mice, where the depletion of B cells caused an infiltration of MAC-3 positive 
cells in the white matter (31.97±15.69 MAC-3+ cells/mm2 white matter) compared to the 
control treated mice (7.01±3.86 MAC-3+ cells/mm2 white matter, p>0.05). 
Since the meninges are the intersection between the peripheral immune cells and the CNS, 
we also investigated them to analyse the differences in this section. The number of 
meningeal B cells was similar in formerly depleted mice and control treated mice as well as 
in rMOG EAE (p>0.05) and in MOG p35-55 EAE (p>0.05) (figure 23). In contrast, the T cell 
number was decreased in the meninges in rMOG EAE compared to control treated mice 
(aCD20 treated 2.17±1.22 meningeal T cells/spinal cord cross section, ctrl treated Ab 
12.31±0.99 meningeal T cells/ spinal cord cross section, p>0.05)), as well as in MOG p35-55 
EAE mice (aCD20 treated 8.33±1.79 meningeal T cells/ spinal cord cross section, ctrl treated 
3.75±1.09 meningeal T cells/ spinal cord cross section, p<0.01). 
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Overall, the B cell repletion is not completed in the white matter but in the meninges. The 
meninges of aCD20 treated mice showed the same amount of B cells compared with the 
control treated mice. This could be observed in rMOG EAE as well as in MOG p35-55 EAE. 
While the T cells in both EAE models were neither repleted in the white matter nor in the 




































Figure 23: Dynamic of B cells, T cells and myeloid cells during B cell repletion. 
a) Representative figures of spinal cord sections stained for B220, CD3 and MAC-3, 14 weeks 
after last aCD20 or ctrl Ab treatment in rMOG or MOG p35-55 EAE. b) shows the according 
quantitative analysis of B220+ CD3+ and MAC+ cells per mm2 white matter (n=5 in rMOG EAE 
and n=4 in MOG p35-55 EAE). In b) and c) the mean of B220+ B and CD3+ T cells in the 
meninges per spinal cord section is shown. d) shows the demyelinated area in percent of white 
matter, n=4 per group. 










The rapid clinical benefit of aCD20 therapy in most MS patients provides a new focus on the role 
of B cells in this disease. Nevertheless, until now a characterization of remaining and reappearing 
B cells is still missing. This study tries to close this gap and reveals new insights which may 
improve the strategy of MS therapy.  
4.1. Enrichment of CD27+ activated B cells after aCD20 treatment 
In MS patients, the blood is the only available compartment to observe and investigate B cell 
populations after aCD20 treatment, whereas diagnostic abilities in secondary lymphoid organs 
such as lymph node and spleen are limited. Therefore, animal models are needed to characterize 
remaining and reappearing B cells in these immune relevant organs. 
In the present study we analysed the frequency and functional properties of remaining and 
reappearing B cells after aCD20 treatment. Nearly no B cells are found in the blood after aCD20 
treatment whereas B cells in spleen, lymph node and especially in the bone marrow are not fully 
depleted by aCD20 (figure 5). The characterization of these remaining B cells in lymph node and 
spleen showed that they express CD20 and are theoretically depletable by aCD20 antibodies. In 
contrast, the remaining B cells in the bone marrow do not express CD20 and could therefore not 
be depleted by aCD20 treatment. These remaining B cells in the bone marrow are most probably 
precursor B cells which, after migration into the periphery. These precursor B cells could also be 
observed in rituximab-treated patients with rheumatoid arthritis115,116. 
The remaining B cells in spleen and lymph node led to the question why some of these B cells in 
spleen and lymph node are not affected by aCD20 treatment. Histological findings in this study 
showed that most of the remaining B cells are located around germinal centre structures in the 
spleen. This result led to the hypothesis that these B cells in germinal centres might be sterically 
protected against aCD20 antibodies or that other mechanisms led to the protection of these 
remaining B cells. Resistance to aCD20 treatment was also described in other animal 
models117,118. The binding of rituximab to the CD20 molecule leads to its translocation to lipid 
rafts. Alterations in lipid raft composition have been associated with reduced efficacy of 
rituximab119. Furthermore, a study in cynomologous monkeys demonstrated that germinal 
centres in lymph node and spleen show a lower sensitivity to aCD20 antibodies117. Our results 
revealed that the remaining B cells in spleen and lymph node are an enrichment of CD27+ B cells 
and are located in germinal centres (figure 5.). This finding is in line with the previous studies 
described above117,120. CD27 is a marker for B cell activation which is involved in B cell expansion 
and furthermore required for germinal centre formation120. Therefore, one hypothesis is that 
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reappearing B cells do not originate from a naïve population residing inside the bone marrow 
but rather originate from a remaining population of activated B cells. In MS patients, the 
recurring reappearance and depletion of B cells could lead to the enrichment of an activated B 
cell phenotype which may contribute to the worsening of the disease course. Additionally, an 
increased resistance to B cell depletion could also be a consequence. Maurer et al.121 provided 
evidence for this hypothesis by demonstrating that after a single course of rituximab treatment, 
increased frequency of IgG+ CD27+ memory B cells were found in MS patients. This argument is 
even more important considering the results of the B cell repletion kinetic in our study. Until 
now it was unclear whether B cells reappear first in the blood or simultaneously in blood and 
other immune relevant compartments. In this study, B cell reappearance in naïve mice started 
first in spleen and bone marrow while the B cell repletion of lymph node and blood lacked 
behind. Conclusively, the blood is not suitable monitoring compartment for B cell reappearance. 
Today, MS patients which are treated with aCD20 are only monitored for reappearance of B cells 
in the blood. When reappearing B cells are detected in the blood, a new treatment course of 
aCD20 treatment is started. Considering the results of our study, a constant treatment schedule 
may be a better treatment strategy to avoid an enrichment of activated B cells. 
 
Figure 24:Schematic overview of the B cell pool before and after B cell depletion. 
B cell depletion enriches the relative amount of CD27+ activated B cells of remaining B cells in 
spleen. 
  4. Discussion 
73 
 
4.2. Reappearance of activated B cells causes clinical worsening of rMOG 
EAE and a different distribution of reappearing B cells during repletion in 
the immune relevant compartments 
In 2010, Weber et al.95 described an EAE model induced by immunization with rMOG in which B 
cells are actively involved and depletion of these B cells results in a clinical benefit. In contrast, 
in the T cell mediated model, induced by immunization with MOG p35-55, animals show a 
clinical worsening after B cell depletion95. In addition to the repletion kinetic after aCD20 
treatment, we further analysed how these reappearing B cells influence the clinical course of 
rMOG and MOG p35-55 immunized mice. In rMOG EAE, a clinical worsening after reappearance 
of B cells is observed in aCD20 treated mice compared to control treated mice. In contrast, mice 
immunized with MOG p35-55 showed a clinical benefit after reappearance of B cells compared 
to the control-treated group. These clinical differences after the reappearance of B cells could 
be explained by the dichotomy of B cells. On one hand, B cells can have regulatory functions 
which are associated with release of IL-10. It was reported that IL-10 deficient mice do to not 
recover from severe EAE but after the transfer of WT IL-10 producing B cells, an improvement 
of the disease course could be observed122. In MS patients, the release of  IL-10 plays a crucial 
role in the recovery from relapses123. On the other hand, B cells have pro-inflammatory features, 
for example the production of IL-6, which leads to the activation of T cells39,124. IL-6 deficient 
mice are reported to be resistant to EAE125. All in all, it could be suggested that B cells of mice 
with rMOG EAE reappear in a B cell-activating milieu and show a more pro-inflammatory 
phenotype which causes the clinical worsening. In contrast, in MOG p35-55 EAE the B cells 
reappeared in a milieu which may induces a more regulatory phenotype leading to an improved 
clinical course of EAE. These findings provide evidence for a different function of these 
reappearing B cells which seems to be dependent on the milieu in which B cells reappear. The 
study of Constant et al.109,126 compared MOG protein EAE to MOG p35-55 EAE and found that B 
cells which were previously activated by an antigen show an increased capacity to act as APCs 
which can successfully prime CD4+ T cells. A further study could confirm these results and 
reported two different mechanisms which can induce EAE. The mechanism depends on the 
nature of the immunogen: on the one hand, MOG p35-55 EAE is mediated by an 
encephalitogenic T cell response, while on the other hand human MOG protein EAE showed an 
encephalitogenic B cell response127. These studies supported our findings that the B cell function 
is influenced by the initial immunogenic stimulus and could explain why reappearing B cells of 
mice in rMOG EAE cause a clinical worsening. 
Further evidence that the B cell function of reappearing B cells depends on the initial stimulus is 
supported by our repletion kinetic data. We could observe differences in the onset of B cell 
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repletion and B cell distribution in the different compartments in the two used EAE models. Mice 
immunized with MOG p35-55 showed a similar repletion kinetic as naïve mice. Together with 
the clinical benefit after reappearance of B cells in these mice, it seems that B cells of mice in 
MOG p35-55 EAE reappeared less activated due to the missing initial B cell-activating stimulus. 
In contrast, in mice with rMOG EAE the repletion started earlier and B cells were more 
distributed in different immune relevant compartments (figure 7). The different repletion 
kinetics and clinical outcome are further evidence for a different phenotype of reappearing B 
cells which depends on the milieu and/or the initial stimulus of B cells during repletion. 
4.3. Reappearing B cells show a more activated phenotype in B cell-
mediated EAE 
In the T cell-mediated model induced by MOG p35-55, reappearing B cells initially showed a high 
expression of CD27 which could not be observed at a later time point after B cell repletion was 
complete. In contrast, in the B cell-mediated rMOG induced model, CD27 expression of 
reappearing B cells remained profoundly increased even after complete reappearance of B cells. 
To analyse the effect of these enriched CD27+ B cells, an in vivo proliferation experiment was 
performed. Data evaluation revealed that the remaining B cells in lymph node and spleen 
showed a higher proliferation rate o observed in mice with rMOG as well as in MOG p35-55 EAE. 
This led to the hypothesis that the reappearing B cells which are detectable around week 7 in 
spleen and lymph node do not originate from the bone marrow but rather expand from these 
remaining B cells. 
This experiment was repeated in both EAE models to verify the hypothesis that reappearing B 
cells expand from the spleen and lymph and do not migrate from the bone marrow. In the spleen 
of aCD20 treated mice immunized with rMOG, a significantly higher proliferation of B cells was 
observed during the phase of B cell repletion compared to control-treated mice. This effect 
could also be observed in MOG p35-55 EAE, albeit at a lower level when compared to rMOG 
EAE. The same trend could be seen in the lymph node but this effect was not statistically 
significant. In the bone marrow, a lower proliferation was observed in all investigated groups. 
These finding support the hypothesis that the remaining CD27+ activated B cells expand from 
the spleen and do not originate from naïve B cells inside the bone marrow. 
In MS patients, remaining IgG+ CD27+ memory B cells were found after a single course of 
rituximab121. Similar to our findings in EAE, Maurer et al.128 also showed in MS a clonal expansion 
of IgM+ memory B cell after rituximab treatment. The analysis of these remaining and expanding 
memory B cells in humans revealed two different pathways for the development of human 
memory B cells. One pathway depends on germinal centres while the other one is independent 
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of germinal centres. Memory B cells derived from primary germinal centre reactions are 
characterized as CD27⁻IgG⁺ and CD27⁺IgM⁺ whereas B cells from consecutive germinal centre 
responses are CD27⁺IgA⁺ and CD27⁺IgG⁺129. Several studies reported an expansion of 
CD27+IgM+IgD− and CD27−IgG+ memory B cells in autoimmune diseases130–132. These findings 
support the hypothesis of an expanding CD27+ B cell population during repletion which could 
be observed in the EAE models in our study.  
For a further analysis of these different B cell phenotypes, isolated B cells were re-stimulated 
with rMOG or MOG p35-55 according to their immunization stimuli and co-cultured with MOG-
specific T cells. The reappearing B cells of aCD20-treated mice immunized with rMOG caused a 
higher proliferation rate of MOG specific T cells compared to control-treated B cells. In contrast, 
the co-culture of MOG-specific T cells and reappearing B cells of MOG p35-55 immunized 
animals showed the opposite results (figure 12). Re-stimulation with rMOG activates the 
reappearing B cells and causes a superior APC function108. Antigen presentation of B cells is 
necessary for the induction of a B cell-dependent EAE, induced by human MOG protein, and 
contributes to the severity of the disease course80,102. In 2013, Molnarfi et al.111 reported that B-
cell MHC II-/-mice were resistant to EAE induced by recombinant human MOG protein since antigen 
presentation in the context of MHC-II is necessary for EAE induction. APC function is necessary 
for the differentiation of CD4+ T cells into pathogenic Th1 and Th17 cells which play an important 
role in the pathogenesis of EAE. It could be suggested that these reappearing B cells with 
superior antigen-presenting function could have caused a clinical worsening in rMOG immunized 
mice through the activation and differentiation of Th1 and Th17 cells. 
Furthermore, a higher amount of the pro-inflammatory cytokines IFN ƴ, IL-17 and IL-6 was 
measured in the co-culture of MOG-specific T cells and reappearing B cells isolated from rMOG 
immunized animals. IL-6 is described as a pro-inflammatory cytokine which induces the 
differentiation of pathogenic Th1 and Th17 cells39,124,125. The cytokines IFN ƴ and IL-17 released 
by of these induced T cells are essential for the pathogenesis of EAE 133,134. In the co-culture of 
reappearing B cells isolated from MOG p35-55 immunized mice, lower concentrations of IFN ƴ 
and IL-17 and higher concentration of IL-6 were observed when compared to their control. 
Nevertheless, the amount of IL-6 produced by reappearing B cells of MOG p35-55 immunized 
animals was still at a lower level when compared to the co-culture with reappearing B cells of 
rMOG immunized mice. These results are in line with the previous findings and could explain the 
clinical benefit after the reappearance of B cells in MOG p35-55 EAE. Regarding these ex vivo 
results, we assumed that the continuous presence of rMOG during EAE stimulated and induced 
a more activated phenotype of B cells with superior antigen presenting function. This more 
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phenotype may leads to an increased priming of pathogenic Th1 and Th17 cells which contribute 
to the clinical worsening. Similar results were demonstrated in a study by Weber et al. where 
they also observed a higher release of IFN ƴ and IL-17 in a co-culture with B cells of rMOG 
immunized mice and naïve T cells95. 
Further evidence that the stimulation of reappearing B cells is dependent on the antigen is 
provided by ex vivo stimulation with LPS and CpG. For this, B cells were stimulated in an antigen-
independent matter by LPS and CpG, which activate TLR signalling. The earliest reappearing cells 
8 weeks after repletion showed no response to either stimulus independent of whether they 
were isolated from mice immunized with rMOG or with MOG p35-55. B cells which were isolated 
from MOG p35-55 immunized animals after full repletion responded to LPS in the same way as 
to CpG but in a weaker manner than B cells of control-treated mice. In contrast, after full B cell 
repletion, reappearing B cells of rMOG immunized animals showed a similar or higher release of 
IL-10 and IL-6. This decreased cytokine release after ex vivo stimulation with TLR agonists may 
be caused by the missing BCR signalling or the TLR response might be inhibited at this stage of 
B cell expansion. Both, BCR and TRL signalling are reported to enhance the immune response135. 
Therefore, the lower cytokine amount released by recently reappearing B cells might be due to 
the missing BCR signalling.  
Drawing a complete picture, the initial stimulus during the reappearance of B cells appears to 
influence the arising B cell phenotype. Reappearing B cells most likely originate from an enriched 
population of CD27+activated B cells which are mostly located in germinal centres in the spleen 
after aCD20 treatment. This location seems to protect these activated B cells from depletion by 
the aCD20 Ab. These remaining CD27+ B cells expand in the spleen and proliferate in mice with 
rMOG EAE to a more activated phenotype which shows superior APC function and induces of 
Th1 and TH17 cells ex vivo. Furthermore, these B cells are more frequent in the immune relevant 
compartments and repletion starts earlier. These reappearing and activated B cells in rMOG EAE 
could be responsible for the worsening clinical course (figure 8).  
In the T cell-mediated EAE this effect is vice versa. The reappearing B cells lead to a clinical 
benefit and show a repletion kinetic similar to the kinetic observed in naïve mice. The 
composition of these reappearing B cell also shows an enrichment of CD27+ activated B cells but 
show a weaker APC function and a reduced induction of Th1 and Th17 cells ex vivo. This effect 
is gone after full repletion of B cells which may be due to the missing stimulus of B cell activation 
in the periphery.  
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In RRMS patients, the cytokine profile is distinct from healthy individuals. MS patients show 
enhanced levels of pro-inflammatory cytokines released by B cells like IL-6, Lymphotoxin (LT) 
and TNF-α, while anti-inflammatory cytokines like IL-10 are decreased136. This pro-inflammatory 
milieu leads in to an increased Th1 and Th17 response which is diminished after B cell-depleting 
therapy40. The presence of these activated pro-inflammatory B cells led to the hypothesis that 
there is a peripheral stimulus in MS patients which activates these B cells. Since clonal expansion 
of remaining B cells is reported in MS patients after rituximab treatment, it is important to create 
an anti-inflammatory milieu during B cell reappearance to avoid relapses. Maurer et al.128 
reported a patient with NMO, a MS related disease, which had a relapse during their study. As 
an explanation for this relapse they suggested a fast clonal expansion of the remaining IgG 
memory B cells induced by an increased BAFF level128.This hypothesis of Maurer et al. fits to the 
findings of our study in rMOG EAE where the reappearance of B cells under B cell activating 
conditions led to a clinical worsening. 




Figure 25: Overview of possible immune mechanisms during reappearance of B cell in rMOG 
and MOG p35-55 EAE, including T cell interaction. 
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4.4. Dynamic of T cells during B cell depletion and repletion after aCD20 
treatment 
In recent studies, the presence and the role of CD20+ T cells were discussed137,138. The existence 
of CD20+ T cell was described by Wilk et al.137 in 2009 in patients with rheumatoid arthritis137. 
Current studies support the hypothesis that these CD20+ T cells are increased in MS patients42. 
Thus, we also investigated the direct and indirect effects of aCD20 treatment on T cells. 
In this study, an increased frequency of T cells was observed in all investigated compartments 
after aCD20, which can be explained by a frequency shift compensating the missing B cell 
population. This increased frequency was reduced when B cells started to reappear and was 
comparable to the frequency in control-treated mice after B cell repletion was completed. This 
observation supports the hypothesis of a frequency shift. In contrast to the T cell frequencies, 
the absolute number of T cells was decreased in the spleen after aCD20 treatment. This finding 
provides initial evidence for a direct aCD20 effect on T cells. This effect of aCD20 treatment on 
T cells has been previously described. Cross et al.139 reported a decreased T cell number in CSF 
of MS patients treated with rituximab. 
Analysing T cell subsets in spleen, lymph node, bone marrow and blood for CD20+ T cells in 
aCD20-and control-treated mice showed a clear CD20+T cell population in control mice which 
was missing in aCD20-treated mice. The analysed population in this study was not clearly distinct 
from CD20- T cells but showed CD20dim expression which is also described for the CD20+ T cell 
population in MS patients and patients with rheumatic athritis137,138. Furthermore, the absence 
of this population after aCD20 treatment serves as an evidence for the existence of this these 
population. A previous study in MS showed a distribution of CD20+ T cells in the CD4+ and CD8+ 
T cell populations which is comparable to our results. Additionally, these CD20+ T cells were also 
reduced upon aCD20 treatment138. In 2014, Holley et al.42 reported that CD20+ and CD20- T cell 
produce IFN and IL-4  after ex vivo stimulation in the blood of MS patients and that CD20+ T cell 
which were positive for IFN41 were found in the brain. Further studies suggest that these CD20+ 
T cell populations mediate inflammation in other autoimmune diseases140,141. These CD20+ T 
cells undergo a shift from Th1 to Th17 cells in rheumatic atritis142. Th17 cells are also found in 
MS lesions26. The fact that aCD20 treatment in this study also reduces this CD20+ T cell 
population and causes a clinical benefit may provide evidence that CD20+ T cells play a role in 
MS pathogenesis and accordingly for the treatment effect of aCD20. However, our study also 
includes findings which may provide evidence against this hypothesis. Repletion of the CD20+ T 
cell population and clinical benefit in rMOG EAE take place at the same point in time and suggest 
that the CD20+ T cell population is somehow involved in the clinical outcome of the disease and 
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that the depletion could cause a clinical benefit. Evidence against this hypothesis is the 
comparable reappearance of CD20+ B cells of mice with rMOG and MOG p35-55 EAE and in 
contrast to mice with rMOG EAE, no worsening of the clinical score was visible after 
reappearance of CD20+ T cells in mice with MOG p35-55 EAE. This could have different reasons. 
For instance, the effect could be overwritten by an increased reappearance of naïve B cells with 
regulatory function or by missing activation of B cells as was observed in mice with rMOG EAE. 
Another reason for this finding could be the limitation of the EAE model which may could not 
show a further worsening in the clinical outcome. Although there is strong evidence for the role 
of CD20+ T cells in MS and EAE, it is not fully understood and further investigations are needed 
to proof these hypotheses. Possible experiments for elucidating the role of CD20+ T cells could 
be the sorting of these CD20+ T cells and ex vivo stimulation to characterize the exact function 
of these T cells. A further worthwhile experiment might be to transfer isolated CD20+ T cells into 
mice with EAE and to analyse the resulting clinical outcome. Another possibility is to exclusively 
deplete this CD20+ T cell population and investigate the outcome of this depletion. Holley et 
al.42 showed that ScFvRit:sFasL, which has a pro-apoptotic activity, efficiently depletes CD20+ T 
cells. 
4.5. Direct stimulation of T cells after aCD20 treatment ex vivo 
Additionally, the repletion of CD20+ T cells was investigated and showed a reappearance of this 
population 8 weeks after the last treatment in naïve mice while full repletion was reached at 
week 12 similar to the B cell repletion kinetic. In conclusion, CD20+ T cells seem to be depletable 
and able to reappear after aCD20 treatment. Due to the fact that this population reappears 
shortly after the B cells, the absence may be due to the missing B cell and T cell interaction.  
Further evidence for an indirect effect on T cells by B cell depletion was gained via the direct ex 
vivo stimulation of isolated T cells. For this, T cells were isolated from naïve mice 8 weeks after 
the last treatment when B cells just started to reappear. These T cells showed a decreased 
proliferation rate and release of IL-17. This effect is gone 12 weeks after the last treatment when 
B cell repletion is complete. 
In order to analyse the direct influence of missing B cells on T cells, T cell isolation and 
stimulation was repeated during the B cell repletion in EAE models. In the B cell-mediated, rMOG 
induced model, as well as in MOG p35-55 EAE the proliferation rate of T cells is decreased 
compared to T cells of control-treated mice 8 weeks after the last aCD20 treatment. The amount 
of released IFN and IL-17 was also reduced after 8 weeks in both EAE models. When B cells are 
fully repleted at week 12 after the last treatment, the proliferation of T cells isolated from 
aCD20-treated mice immunized with rMOG is higher compared to control-treated mice whereas 
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the T cell proliferation in aCD20-treated mice immunized with MOG p35-55 is decreased 
compared to their control-treated animals. The same tendency is seen for the released IFN ƴ 
and IL-17 in the supernatant after T cell stimulation of T cells from mice with MOG p35-55 EAE. 
The cytokine release of T cells of aCD20-treated mice immunized with rMOG is not significantly 
different compared to control-treated mice. In MOG p35-55 EAE instead released cytokines of 
aCD20-treated T cells are significantly decreased compared to control-treated mice. The results 
of this experiment support the previous findings which showed that reappearing B cells in rMOG 
EAE have a more activated phenotype and showed ex vivo a superior APC function. 8 weeks after 
the last aCD20 treatment an overall lower number of B cells was present and could not efficiently 
activate T cells whereas after 12 weeks, when B cells are fully reappeared an efficient T cell 
activation is possible. In MOG p35-55 EAE, the proliferation as well as IL-17 and IFN release is 
lower after full repletion of B cells. Due to the weaker APC function of reappearing B cells and 
thereby following lower rate of activated T cells in aCD20-treated mice this, result is in line with 
the previous results. Similar results were seen in rituximab-treated patients. It was reported that 
T cells showed a decreased expression of T cell activation markers, pro-inflammatory cytokine 
production and proliferation capacity141. This inhibition of T cell activation may contribute to the 
clinical benefit of aCD20 treatment in MS patients as well as in rMOG EAE. 
 
Figure 26:Overview of T cell function after aCD20 treatment. 
Decreased proliferation and cytokine release during B cell proliferation which switch into high 
proliferation and cytokine release after full repletion of B cells 
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4.6. Compensation by MAC-3+ cells and meningeal B cells but not by T cells 
Analysing the inflammation and demyelination after aCD20 treatment in mice with rMOG and 
MOG p35-55 EAE, no difference in demyelination of the spinal cord could be observed between 
aCD20-treated and control-treated mice in both EAE models. A reduction of B cells and T cells in 
the white matter of the aCD20 treated mice compared to control-treated mice was observed at 
the point of time when peripheral B cells are completely reappeared. In contrast, the number of 
myeloid MAC-3+ cells is increased in the white matter after aCD20 treatment. Additionally, the 
analysis of meningeal cells showed a full repletion of B cells but not T cells. Summarizing these 
findings, MAC-3+ cells and infiltrating meningeal B cells seem to compensate the missing B and 
T cell numbers in the white matter. Lehmann-Horn et al.143 described an increased activation of 
peripheral myeloid cells in MOG p35-55 EAE after aCD20 treatment. The same effect was seen 
for human PBMCs143. This peripheral activation can lead to migration and infiltration of myeloid 
cells into the CNS, which is seen in this study. Another possible explanation of the missing 
differences between the groups may lead to the limited explanatory value of the EAE model. 
Comparing the scores in rMOG EAE, the scores of control-treated mice stay nearly at the 
maximum whereas the scores of aCD20-treated mice further increased after reappearance of 
more activated B cells. These reappearing B cells in rMOG EAE induced ex vivo pathogenic Th1 
and Th17 cells. These T cells could cause more demyelination and adjust demyelination of 
aCD20-treated and control-treated mice to the same level. Furthermore, in MOG p35-55 EAE, 
the reappearance of B cells led to an improvement of the clinical scores of aCD20-treated mice 
which showed a more severe disease score compared to control-treated mice during the phase 
of B cell depletion. In MOG p35-55 EAE the aCD20-treated group showed after EAE onset a 
nearly maximal disease score. Due to this fact, no decreased demyelination could be observed 
in these mice even after reappearance of B cells with a more naive function. Here the value and 
modulation of these EAE models induced with the used immunization regime seems to be 
limited and could not answer the question whether the different phenotype of reappearing B 
cells has an influence on the CNS demyelination.  
Summarizing the findings of this study, in the two used EAE models, the reappearance of B cell 
after aCD20 treatment has different effect on clinical course. These differences are caused by a 
different phenotype of the reappearing B cells with different functional capacities. After 
depletion, the remaining B cell population showed an enrichment of CD27+ activated B cells 
which expanded in the spleen and then became activated by rMOG, which seems to create a B 
cell activating milieu. In contrast, mice in MOG p35-55 EAE, the milieu in which B cells reappear 
does not seem to be B cell activating. The different activation induced two different phenotypes 
of B cells. The phenotype of reappearing B cells in mice of rMOG EAE is more activated and leads 
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to a superior APC function which induces pathogenic Th1 and Th17 cells. The phenotype of 
reappearing B cells in mice with MOG p35-55 EAE is more naïve and leads to weaker APC 
function. This finding led to the hypothesis that the phenotype of reappearing B cells depends 
on immunogenic stimulus during their reappearance. 
In MS patients, the status of B cells and influencing the milieu should be controlled during 
reappearance. Further, a continuous depletion might be a better treatment schedule than 
monitoring reappearance of B cells in the blood. Repeating depletion and reoccurring repletion 
in secondary lymphoid organs could enrich remaining IgG+ memory B cells which undergo clonal 
expansion. Enrichment of these cells may facilitate a relapse130–132. Another strategy to avoid 
pathogenic reappearance of B cells could be to modulate the milieu during reappearance and to 
control the phenotype of these B cells. A promising possibility is to inhibit BCR signalling and 
avoid stimulation of B cells. Bruton's tyrosine kinase (BTK) is required for B-cell receptor-
dependent NF-kappaB signalling pathway144. BTK inhibition is under investigation in EAE and MS. 
Combination therapy of ofatumumab, a humanised aCD20 antibody, and BTK inhibitor PCI-
32765 showed good response in patients with chronic lymphocytic leukemia/small lymphocytic 
lymphoma (CLL/SLL) and related diseases145. 
 
A further possibility to prevent B and T cell interaction is the inhibition of costimulatory 
molecules such as CD80, CD86 or/ and CD40. Anti-inflammatory drugs may represent one 
possibility. IFNβ therapy decreased the levels of CD80, CD86 on human PBMC as well as the level 
of BAFF in MS patients. One clinical trial reported that combination therapy of rituximab and 
IFNβ showed no difference in clinical parameters, MRI and laboratory outcomes146,147. Inhibiting 
the APC function of these B cells could be a particularly successful strategy. 
Optimising MS therapy during and after aCD20 treatment a B cell activating medication should 
be avoided B cell activating treatment may not should be combined with aCD20 treatment. 
This study could reveal new insights in the characterization of B cells, provides a greater 
understanding of EAE pathogeneses after aCD20 Ab depletion and further hints towards 
optimising MS therapeutic strategy. 
In conclusion, there is a range of evidence as to which effect of aCD220 treatment causes clinical 
benefit in MS patients. On the one hand the missing B cell population led to the hypothesis that 
depletion of B cells causes the clinical benefit. On the other hand we showed that the depletion 
of CD20+ T cells in rMOG as well as in MOG p35-55 EAE is possible by aCD20 treatment. These 
direct effects on T cells could also cause benefits of aCD20 treatment in MS patients. 
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Furthermore, T cells are affected by the indirect effect of aCD20 treatment, missing B cell 
interaction. T cells of aCD20-treated mice showed a reduced proliferation rate after direct 
stimulation 8 weeks after the last treatment in rMOG, MOG p35-55 EAE and naïve mice. This 
effect is gone in rMOG immunized mice after full repletion but not in MOG p35-55 immunized 
mice. Knowing the influence of aCD20 treatment on T cell gives new insight in MS pathology and 
new therapeutic strategies. Specific depletion of these CD20+ T cells could have beneficial effect 
and avoid side effect of long-term treatment. Until today, the exact cause of clinical benefit is 
not known and could also be a combination of direct B cell and CD20+ T cell depletion and 
missing B cell interaction. 
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